

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number  
**WO 02/056893 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/702**,  
C07H 15/04, 3/06, A61P 1/04, 31/04

(74) Agent: **OY JALO ANT-WUORINEN AB**; Iso  
Roobertinkatu 4-6 A, FIN-00120 Helsinki (FI).

(21) International Application Number: PCT/FI02/00043

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 18 January 2002 (18.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
20010118 19 January 2001 (19.01.2001) FI

(71) Applicant (*for all designated States except US*): **CARBION OY** [FI/FI]; Viikinkaari 9, FIN-00710 Helsinki (FI).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MILLER-PO-DRAZA, Halina** [SE/SE]; Lantmilsgatan 20, S-42137 Västra Frölunda (SE). **TENEBERG, Susann** [SE/SE]; PL 1639, S-43063 Hindås (SE). **ÅNGSTRÖM, Jonas** [SE/SE]; de Geersgatan 12, S-41657 Göteborg (SE). **KARLSSON, Karl-Anders** [SE/SE]; Nilssonsberg 37, S-41143 Göteborg (SE). **NATUNEN, Jari** [FI/FI]; Meritullinkatu 6 C 18, FIN-00170 Helsinki (FI).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL RECEPTORS FOR *SI*(*HELICOBACTER PYLORI*) AND USE THEREOF

(57) Abstract: The present invention describes a substance or a receptor comprising *Helicobacter pylori* binding oligosaccharide sequence [Gal(A)<sub>q</sub>(NAc)<sub>r</sub>/Glc(A)<sub>s</sub>(NAc)<sub>t</sub>,α3/β3]<sub>s</sub>[Galβ4GlcNAcβ3]<sub>t</sub>Galβ4Glc(NAc)<sub>u</sub> wherein q, r, s, t, and u are each independently 0 or 1, and the use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of *Helicobacter pylori*. The invention is also directed to the use of the receptor for diagnostics of *Helicobacter pylori*.



WO 02/056893 A1

## Novel receptors for *Helicobacter pylori* and use thereof.

### FIELD OF THE INVENTION

5 The present invention describes a substance or receptor binding to *Helicobacter pylori*, and use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of *Helicobacter pylori*. The invention is also directed to the use of the receptor for diagnostics of *Helicobacter pylori*.

### 10 BACKGROUND OF THE INVENTION

*Helicobacter pylori* has been implicated in several diseases of the gastrointestinal tract including chronic gastritis, non-steroidal anti-inflammatory drug (NSAID) associated gastric disease, duodenal and gastric ulcers, gastric MALT lymphoma, and gastric adenocarcinoma  
15 (Axon, 1993; Blaser, 1992; DeCross and Marshall, 1993; Dooley, 1993; Dunn *et al.*, 1997; Lin *et al.*, 1993; Nomura and Stemmermann, 1993; Parsonnet *et al.* 1994; Sung *et al.*, 2000 Wotherspoon *et al.*, 1993). Totally or partially non-gastrointestinal diseases include sudden infant death syndrome (Kerr *et al.*, 2000 and US 6,083,756), autoimmune diseases such as autoimmune gastritis and pernicious anaemia (Appelmelk *et al.*, 1998; Chmiela *et al.*, 1998;  
20 Clayes *et al.*, 1998; Jassel *et al.*, 1999; Steininger *et al.*, 1998) and some skin diseases (Rebora *et al.*, 1995), pancreatic disease (Correa *et al.*, 1990), liver diseases including adenocarcinoma (Nilsson *et al.*, 2000; Avenaud *et al.*, 2000) and heart diseases such as atherosclerosis (Farsak *et al.*, 2000). Multiple diseases caused or associated with *Helicobacter pylori* has been reviewed (Pakodi *et al.*, 2000). Of prime interest with respect  
25 to bacterial colonization and infection is the mechanism(s) by which this bacterium adheres to the epithelial cell surfaces of the gastric mucosa.

Glycoconjugates, both lipid- and protein-based, have been reported to serve as receptors for the binding of this microorganism as, e.g., sialylated glycoconjugates (Evans *et al.*, 1988),  
30 sulfatide and GM3 (Saitoh *et al.*, 1991), Le<sup>b</sup> determinants (Borén *et al.*, 1993), polyglycosylceramides (Miller-Podraza *et al.*, 1996; 1997a), lactosylceramide (Ångström *et al.*, 1998) and gangliotetraosylceramide (Lingwood *et al.*, 1992; Ångström *et al.*, 1998). Other potential receptors for *Helicobacter pylori* include the polysaccharide heparan sulphate (Ascensio *et al.*, 1993) as well as the phospholipid phosphatidylethanolamine  
35 (Lingwood *et al.*, 1992).

US patents of Zopf *et al.*: 5,883,079 (March 1999), 5,753,630 (May 1998) and 5,514,660 (May, 1996) describe Neu5Ac $\alpha$ 3Gal- containing compounds as inhibitors of the *H. pylori*

adhesion. The sialyl-lactose molecule inhibits *Helicobacter pylori* binding to human gastrointestinal cell lines (Simon *et al.*, 1999) and is also effective in a rhesus monkey animal model of the infection (Mysore *et al.*, 2000). The compound is in clinical trials.

5 US patent Krivan *et al.* 5,446,681 (November 1995) describes bacterium receptor antibiotic conjugates comprising an asialo ganglioside coupled to a penicillin antibiotic. Especially is claimed the treatment of *Helicobacter pylori* with the amoxicillin-asialo-GM1 conjugate. The oligosaccharide sequences/glycolipids described by the invention do not belong to the ganglioseries of glycolipids.

10


US patents of Krivan *et al.*: 5,386,027 (January 1995) and 5,217,715 (June 1993) describe use of oligosaccharide sequences or glycolipids to inhibit several pathogenic bacteria, however the current binding specificity is not included and *Helicobacter pylori* is not among the bacteria studied or claimed.

15

The saccharide sequence GlcNAc $\beta$ 3Gal has been described as a receptor for *Streptococcus* (Andersson *et al.*, 1986). Some bacteria may have overlapping binding specificities, but it is not possible to predict the bindings of even closely related bacterial adhesins. In case of *Helicobacter pylori* the saccharide binding molecules, except the Lewis b binding protein  
20 are not known.

## SUMMARY OF THE INVENTION

The present invention relates to use of a substance or receptor binding to  
25 *Helicobacter pylori* comprising the oligosaccharide sequence



wherein q, r, s, t, and u are each independently 0 or 1,

30

so that when t = 0 and u = 0, then the oligosaccharide sequence is linked to a polyvalent carrier or present as a free oligosaccharide in high concentration, and analogs or derivatives of said oligosaccharide sequence having binding activity to *Helicobacter pylori* for the production of a composition having *Helicobacter pylori*  
35 binding or inhibiting activity.

Among the objects of the invention are the use of the *Helicobacter pylori* binding oligosaccharide sequences described in the invention as a medicament, and the use of the same for the manufacture of a pharmaceutical composition, particularly for the treatment of any condition due to the presence of *Helicobacter pylori*.

5

The present invention also relates to the methods for the treatment of conditions due to the presence of *Helicobacter pylori*. The invention is also directed to the use of the receptor(s) described in the invention as *Helicobacter pylori* binding or inhibiting substance for diagnostics of *Helicobacter pylori*.

10

Another object of the invention is to provide substances, pharmaceutical compositions and nutritional additives or compositions containing *Helicobacter pylori* binding oligosaccharide sequence(s).

15 Other objects of the invention are the use of the above-mentioned *Helicobacter pylori* binding substances for the identification of bacterial adhesin, the typing of *Helicobacter pylori*, and the *Helicobacter pylori* binding assays.

20 Yet another object of the invention is the use of the above-mentioned *Helicobacter pylori* binding substances for the production of a vaccine against *Helicobacter pylori*.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 **Figs. 1A and 1B.** EI/MS of permethylated oligosaccharides obtained from hexaglycosylceramide by endoglycoceramidase digestion. Gas chromatogram of the oligosaccharides (top) and EI/MS spectra of peaks A and B, respectively (bottom).

30 **Figs. 2A and 2B.** Negative-ion FAB mass spectra of hexa- (2A) and pentaglycosylceramide (2B).

**Figs. 3A and 3B.** Proton NMR spectra showing the anomeric region of the six-sugar glycolipid (3A) and the five-sugar glycolipid (3B). Spectra were acquired overnight to get good signal-to-noise for the minor type 1 component.

35

**Figs. 4A, 4B and 4C.** Enzymatic degradation of rabbit thymus glycosphingolipids. Silica gel thin layer plates were developed in C/M/H<sub>2</sub>O, (60:35:8, by vol.). 4A and 4B, 4-methoxybenzaldehyde visualized plates. 4C, autoradiogram after overlay with

<sup>35</sup>S-labeled *Helicobacter pylori*. 1, heptaglycosylceramide (structure 1, Table I); 2, desialylated heptaglycosylceramide (obtained after acid treatment); 3, desialylated heptaglycosylceramide treated with  $\beta$ 4-galactosidase; 4, heptaglycosylceramide treated with sialidase and  $\beta$ 4galactosidase; 5, reference glycosphingolipids from human erythrocytes (lactosylceramide, trihexosylceramide and globoside); 6, desialylated heptaglycosylceramide treated with  $\beta$ 4-galactosidase and  $\beta$ -hexosaminidase; 7, heptaglycosylceramide treated with sialidase,  $\beta$ 4-galactosidase and  $\beta$ -hexosaminidase.

**Figs. 5A and 5B.** TLC of products obtained after partial acid hydrolysis of rabbit thymus heptaglycosylceramide (structure 1, Table I). Developing solvent was as for Fig. 4A, 4B and 4C. **5A**, 4-methoxybenzaldehyde-visualized plate; **5B**, autoradiogram after overlay with <sup>35</sup>S-labeled *Helicobacter pylori*. 1, heptaglycosylceramide; 2, desialylated heptaglycosylceramide (acid treatment); 3, pentaglycosylceramide; 4, hydrolysate; 5, reference glycosphingolipids (as for Figs. 4A, 4B and 4C).

**Figs. 6A and 6B.** Dilution series of glycosphingolipids. The binding activity on TLC plates was determined using bacterial overlay technique. TLC developing solvent was as for Figs. 4A, 4B and 4C. Different glycolipids were applied to the plates in equimolar amounts. Quantification of the glycolipids was based on hexose content. **6A**, hexa- and pentaglycosylceramides (structures 2 and 3, Table I); **6B**, penta- and tetraglycosylceramides (structures 4 and 5, Table I). The amounts of glycolipids (expressed as pmols) were as follows: 1, 1280 (of each); 2, 640; 3, 320; 4, 160; 5, 80; 6, 40; 7, 20 pmols (of each).

**Figs. 7A and 7B.** Thin-layer chromatogram with separated glycosphingolipids detected with 4-methoxybenzaldehyde (**7A**) and autoradiogram after binding of radiolabeled *Helicobacter pylori* strain 032 (**7B**). The glycosphingolipids were separated on aluminum-backed silica gel 60 HPTLC plates (Merck) using chloroform/methanol/water 60:35:8 (by volume) as solvent system. The binding assay was done as described in the "Materials and methods" section.

Autoradiography was for 72 h. The lanes contained:

- lane 1) Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer (neolactotetraosylceramide), 4  $\mu$ g;
- lane 2) Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer (B5 glycosphingolipid), 4  $\mu$ g;
- lane 3) Gal $\alpha$ 3Gal $\beta$ 4GlcNH $_2$  $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer, 4  $\mu$ g;
- lane 4) Gal $\alpha$ 3(Fuc $\alpha$ 2)Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer (B6 type 2 glycosphingolipid), 4  $\mu$ g;

- lane 5) GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer, 4  $\mu$ g;  
 lane 6) Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer, 4  $\mu$ g;  
 lane 7) GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer (x<sub>2</sub> glycosphingolipid), 4  $\mu$ g;  
 lane 8) NeuAc $\alpha$ 3GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer (NeuAc-x<sub>2</sub>), 4  $\mu$ g;  
 5 lane 9) Fuca $\alpha$ 2Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer (H5 type 2 glycosphingolipid), 4  $\mu$ g;  
 lane 10) NeuAc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer  
 (sialylneolactotetraosylceramide), 4  $\mu$ g. The sources of the glycosphingolipids  
 are the same as given in Table 2.

10

- Figs. 8A, 8B, 8C and 8D.** Calculated minimum energy conformations of three  
 glycosphingolipids which bind *Helicobacter pylori*:  
 GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (**8A**),  
 GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (**8B**) and  
 15 Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (**8C**). Also shown is the non-binding  
 Gal $\alpha$ 3Gal $\beta$ 4GlcNH<sub>2</sub> $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer structure (**8D**). Top views of the  
 oligosaccharide part of each of the calculated minimum energy structures are  
 also shown. Despite differences in anomericity, absence or presence of an  
 acetamido group, axial or equatorial position of the 4-OH of the terminal sugar  
 20 and the fact that the ring plane of the terminal  $\alpha$ 3-linked compounds is raised  
 somewhat above the corresponding plane of the one being  $\beta$ 3-linked, a  
 substantial topographical similarity exists between these structures and also the  
 GlcNAc $\beta$ 3-terminated structure derived from rabbit thymus (see Fig. 9A), thus  
 explaining their similar affinities for the bacterial adhesin. In contrast, the  
 25 acetamido group of the internal GlcNAc $\beta$ 3 is essential for binding (*cf.* **8C** and  
**8D**).

- Figs. 9A, 9B, 9C and 9D.** Calculated minimum energy conformations of the  
 binding-active glycosphingolipids GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer  
 30 (**9A**) and  
 Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4-GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (**9B**) and the non-binding  
 glycosphingolipids NeuAc $\alpha$ 3GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (**9C**) and  
 Gal $\alpha$ 3(Fuca $\alpha$ 2)Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (**9D**). The latter two extensions  
 (**9C** and **9D**) abolish binding of *Helicobacter pylori* while the former (**9B**) is  
 35 tolerated but results in a reduced affinity. Together with the finding that de-*N*-  
 acylation of the acetamido moiety of the internal GlcNAc of B5 (Figs. 8A, 8B, 8C  
 and 8D) completely abolishes binding, the part constituting the binding epitope

must consist of the terminal trisaccharide of B5 shown in Fig. 8C since the acetamido group of a terminally situated *N*-acetylgalactosamine is non-essential.

**Fig. 10.** Minimum energy conformer of the seven-sugar compound NeuGc $\alpha$ 3Gal $\beta$ 4-GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer shown in two projections rotated 90 degrees relative each other. The terminal carbon atom of the glycolyl moiety of the sialic acid as well as the methyl carbon atoms of the acetamido groups of the two internal GlcNAc residues are indicated in black only in order to facilitate the viewer's orientation. For the Glc $\beta$ Cer linkage the extended conformation was arbitrarily chosen for presentation but the minimum binding sequence GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3 is most likely better exposed toward an approaching adhesin in Glc $\beta$ Cer conformations other than the one shown here.

**Figs. 11A, 11B and 11C.** Binding of the monoclonal antibody TH2 (11B) and the lectin from *E. cristagalli* (11C) to total non-acid glycosphingolipid fractions from epithelial cells from human gastric mucosa, human granulocytes and human erythrocytes separated on thin-layer chromatograms. In (11A) the same fractions are shown with 4-methoxybenzaldehyde staining. Autoradiography was in cases (11B) and (11C) performed for twelve hours. In lanes 1-6 80  $\mu$ g of the total non-acid fractions from epithelial cells from human gastric mucosa of five different blood group A individuals were applied, whereas in lane 6 40  $\mu$ g from the total non-acid fraction from human granulocytes and in lane 7 40  $\mu$ g from the total non-acid fraction from human erythrocytes were applied. The overlay assays were performed as described in "Materials and methods".

## DETAILED DESCRIPTION OF THE INVENTION

The present invention describes a family of specific oligosaccharide sequences binding to *Helicobacter pylori*. Numerous naturally occurring glycosphingolipids were screened by thin-layer overlay assay (Table 2). The structures of the glycosphingolipids used were characterized by proton NMR and mass spectrometric experiments. Molecular modeling was used to compare three dimensional structures of the substances binding to *Helicobacter pylori*.

The novel binding specificity was demonstrated by comparing four pentasaccharide glycolipids. It was found that the exchange of the non-reducing end terminal saccharide in GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer by either GalNAc $\beta$ 3 (short name x2 GSL), GalNAc $\alpha$ 3 or Gal $\alpha$ 3 (B5) all resulted in binding of *Helicobacter pylori*, despite differences in anomericity, absence or presence of an acetamido moiety and axial/equatorial position of

the 4-OH. The specificity also includes structures with weaker binding to *Helicobacter pylori*: a shorter form Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer and  $\beta$ 4-elongated forms of the glycolipid with terminal N-acetylglucosamine:

Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer and

- 5 NeuGc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer. In contrast to previously known sialic acid depending specificities (Evans *et al.*, 1988; Miller-Podraza *et al.*, 1996; 1997a), the N-glycolyl neuraminic acid of the last mentioned glycosphingolipid could be released without effect to the binding of *Helicobacter pylori*.
  
- 10 The binding to GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer was very reproducible, though the general saccharide bindings of *Helicobacter pylori* suffer from phase variations of the bacterium, and high affinity of the binding was visible in the overlay assay at low picomolar amounts of the glycolipid.
  
- 15 The length of the binding epitope was indicated by experiments showing that GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, and Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (a shortened form and N-deacetylated forms of the active species) were not binding to *Helicobacter pylori*. The data reveal that the inner GlcNAc residue participates in binding but does not create strong enough binding alone. The
- 20 binding epitope was considered to be the terminal trisaccharide in the pentasaccharide epitopes discussed above. When only two of the residues are present as in Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, binding is weaker, and in the hexasaccharide glycolipid Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer the terminal Gal $\beta$ 4 inhibits the binding, explaining the weaker activity. A heptasaccharide glycolipid having Gal $\alpha$ 3 on the less active
- 25 hexasaccharide glycolipid structure, Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, had higher activity also indicating that terminal trisaccharide epitopes are required for good binding activity.
  
- 30 Specificity of the binding was characterized by assaying isomers and modified forms of the active species. Elongated forms of Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer having the following modifications on the terminal Gal: Fuc $\alpha$ 2 (short name H5-2), Fuc $\alpha$ 2 and Gal/GalNAc $\alpha$ 3 (B6-2, A6-2), Neu5Ac $\alpha$ 3 or Neu5Ac $\alpha$ 6 (sialylparaglobosides), or Gal $\alpha$ 4 (P1) were inactive in the binding assays with *Helicobacter pylori*. The binding was also destroyed by having a  $\beta$ 6-linked branch inner galactose, shown by the structure
- 35 Gal $\beta$ 4GlcNAc $\beta$ 3(Gal $\beta$ 4GlcNAc $\beta$ 6)Gal $\beta$ 4Glc $\beta$ Cer. The branch has been shown to change the presentation of the Gal $\beta$ 4GlcNAc $\beta$ 3-epitope and the disaccharide binding site is probably sterically hindered (Teneberg *et al.*, 1994). (However the result shows that the inner galactose residue to which the disaccharide- or trisaccharide binding epitopes are



bound by  $\beta 3$ -linkage may also contribute to binding.) Furthermore Neu5Ac $\alpha 3$ GalNAc $\beta 3$ Gal $\beta 4$ GlcNAc $\beta 3$ Gal $\beta 4$ Glc $\beta$ Cer (an elongated form of the binding active x2-glycosphingolipid) or GalNAc $\beta 3$ Gal $\alpha 3$ Gal $\beta 4$ GlcNAc $\beta 3$ Gal $\beta 4$ Glc $\beta$ Cer (elongated B5 GSL) did not appear to bind to *Helicobacter pylori*.

5

Molecular modeling was used to compare the active binding structures and inactive species. Calculated minimum energy conformers of the four pentasaccharide glycosphingolipids (Gal $\beta 4$ GlcNAc $\beta 3$ Gal $\beta 4$ Glc $\beta$ Cer with elongation by either GlcNAc $\beta 3$ , GalNAc $\beta 3$ , GalNAc $\alpha 3$  or Gal $\alpha 3$ ) show that conformations of the compounds may closely mimic each other. The conformations of the inactive glycolipids were different. Despite the fact that the terminal saccharides differ also in their anomeric linkage (two alfa- and two beta-linked), molecular modeling revealed that the minimum energy structures are topographically very similar. The differences of the terminal structures are that Gal $\alpha 3$  lacks an acetamido group present in the other three, Gal and GalNAc have the 4-OH in the axial position and GlcNAc in the equivatorial position, and the ring planes of the alfa anomeric terminal are raised slightly above the corresponding plane in the beta anomeric ones. The elongation of the terminal is allowed on position 4 of GlcNAc, also indicating that the 4-OH is not very important for the binding, though the Gal $\beta 4$  elongation causes steric interference. In conclusion, neither the position of 4-OH nor the absence/presence of an acetamido group nor the anomeric structure of terminal monosaccharide residue appear to be crucial for binding to occur, since all the four pentasaccharide glycolipids have similar affinities for the *Helicobacter pylori* adhesin.

10

15

20

25

30

In the light of these rules of binding four other terminal monosaccharides in the binding substance may also provide trisaccharide binding epitopes: Gal $\beta 3$ Gal $\beta 4$ GlcNAc, GlcNAc $\alpha 3$ Gal $\beta 4$ GlcNAc, Glc $\beta 3$ Gal $\beta 4$ GlcNAc and Glc $\alpha 3$ Gal $\beta 4$ GlcNAc. These are analogous to the sequences studied only having differences in the anomeric, 4-epimeric or on C2 NAc/OH structures. The first one is present on a glycolipid from human erythrocytes, while the last three are not known from human tissues so far, but could rather represent analogues of the natural receptor.

35

The binding epitope was shown to include the terminal trisaccharide element of active pentasaccharide glycolipids, and at least in larger repetitive *N*-acetyllactosamines the epitope may be also in the middle of the saccharide chain. The inventors realize that the binding epitopes can be presented in numerous ways on natural or biosynthetically produced glycoconjugates and oligosaccharides such as O-linked or N-linked glycans of glycoproteins and on poly-*N*-acetyllactosamine oligosaccharides. Chemical and enzymatic synthesis methods, especially in the carbohydrate field, allow production of almost an infinite number

of derivatives and analogs. The size of the binding epitope allows some modifications, as exemplified on the C1, C2 and C4 of the terminal monosaccharide, by loss of the non-reducing terminal monosaccharide or elongation from C4 of terminal GlcNAc of GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc, e.g., the position C4 of GlcNAc $\beta$ 3 can be linked to an oligosaccharide chain by a glycosidic bond. When the oligosaccharide sequence is GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, position C4 of terminal GlcNAc $\beta$ 3 can be linked to Gal $\beta$ 1- or an oligosaccharide chain by a glycosidic bond. Especially the C2 and C4 positions of the non-reducing terminal monosaccharide residue in the trisaccharide epitope and the reducing ends of the epitopes can be used for making derivatives and oligomeric or polymeric conjugates having binding activity to *Helicobacter pylori*. The C6 positions of the monosaccharide residues can also be used to produce derivatives and analogs, especially the C6 position of the non-reducing terminal residue in trisaccharide sequence and the reducing end residue of di- and trisaccharide binding substances are preferred.

In this invention the terms "analog" and "derivative" are defined as follows. According to the present invention it is possible to design structural analogs or derivatives of the *Helicobacter pylori* binding oligosaccharide sequences. Thus, the invention is also directed to the structural analogs of the substances according to the invention. The structural analogs according to the invention comprises the structural elements important for the binding of *Helicobacter pylori* to the oligosaccharide sequences. For design of effective structural analogs it is important to know the structural element important for the binding between *Helicobacter pylori* and the saccharides. The important structural elements are preferably not modified or these are modified by very close mimetic of the important structural element. These elements preferably include the 4-, and 6-hydroxyl groups of the Gal $\beta$ 4 residue in the trisaccharide and disaccharide epitopes. Also the positioning of the linkages between the ring structures is an important structural element. For a high affinity binding the acetamido group or acetamido mimicking group is preferred in the position corresponding to the acetamido group of the reducing end-GlcNAc of the di- or trisaccharide epitopes. Acetamido group mimicking group may be another amide, such as alkylamido, arylamido, secondary amine, preferentially N-ethyl or N-methyl, O-acetyl, or O-alkyl for example O-ethyl or O-methyl. For high affinity binding amide derivatives from carboxylic acid group of the terminal uronic acid and analogues thereof are preferred. The activity of non-modified uronic acid is considered to rise in lower pH.

The structural derivatives according to the invention are oligosaccharide sequences according to the invention modified chemically so that the binding to the *Helicobacter pylori* is retained or increased. According to the invention it is preferred to derivatize one or several of the hydroxyl or acetamido groups of the oligosaccharide sequences. The invention describes several positions of the molecules which could be changed when preparing the analogs or the derivatives. The hydroxyl or acetamido groups which tolerate at least certain modifications are indicated by R-groups in Formula 1.

10

Bulky or acidic substituents and other structures, such as monosaccharide residues, are not tolerated at least when linked in the position of the C2, C3 or C6 -hydroxyls of the Gal $\beta$ 4GlcNAc and on C3-hydroxyl non-reducing terminal monosaccharide of the trisaccharide epitopes. Methods to produce oligosaccharide analogs for the binding of a lectin are well known. For example, numerous analogs of sialyl-Lewis x oligosaccharide has been produced, representing the active functional groups different scaffold, see page 12090 Sears and Wong 1996. Similarly analogs of heparin oligosaccharides has been produced by Sanofi corporation and sialic acid mimicking inhibitors such as Zanamivir and Tamiflu (Relenza) for the sialidase enzyme by numerous groups. Preferably the oligosaccharide analog is build on a molecule comprising at least one six- or five-membered ring structure, more preferably the analog contains at least two ring structures comprising 6 or 5 atoms. A preferred analogue type of the oligosaccharide comprise a terminal uronic acid amide or analogue linked to Gal $\beta$ 4GlcNAc-saccharide mimicking structure.

Alternatively terminal uronic acid amide is 1-3-linked to Gal, which is linked to the GlcNAc mimicking structure. In mimicking structures monosaccharide rings may be replaced rings such as cyclohexane or cyclopentane, aromatic rings including benzene ring, heterocyclic ring structures may comprise beside oxygen for example nitrogen and sulphur atoms. To lock the active ring conformations the ring structures may be interconnected by tolerated linker groups. Typical mimetic structure may also comprise peptide analog-structures for the oligosaccharide sequence or part of it.

The effects of the active groups to binding activity are cumulative and lack of one

group could be compensated by adding an active residue on the other side of the molecule. Molecular modelling, preferably by a computer can be used to produce analog structures for the *Helicobacter pylori* binding oligosaccharide sequences according to the invention. The results from the molecular modelling of several  
5 oligosaccharide sequences are given in examples and the same or similar methods, besides NMR and X-ray crystallography methods, can be used to obtain structures for other oligosaccharide sequences according to the invention. To find analogs the oligosaccharide structures can be “docked” to the carbohydrate binding molecule(s) of *H.pylori*, most probably to lectins of the bacterium and possible additional  
10 binding interactions can be searched.

It is also noted that the monovalent, oligovalent or polyvalent oligosaccharides can be activated to have higher activity towards the lectins by making derivative of the oligosaccharide by combinatorial chemistry. When the library is created by  
15 substituting one or few residues in the oligosaccharide sequence, it can be considered as derivative library, alternatively when the library is created from the analogs of the oligosaccharide sequences described by the invention. A combinatorial chemistry library can be built on the oligosaccharide or its precursor or on glycoconjugates according to the invention. For example, oligosaccharides with variable reducing  
20 end can be produced by so called carbohydrid technology

.  
In a preferred embodiment a combinatorial chemistry library is conjugated to the *Helicobacter pylori* binding substances described by the invention. In a more preferred embodiment the library comprises at least 6 different molecules. Preferably the  
25 combinatorial chemistry modifications are produced by different amides from carboxylic acid group on  $R_3$  according to Formula 1. Group to be modified in  $R_3$  may be also an aldehyde or amine or another type of reactive group. Such library is preferred for use of assaying microbial binding to the oligosaccharide sequences according to the invention. Aminoacids or collections of organic amides are commercially available, which substances  
30 can be used for the synthesis of combinatorial library of uronic acid amides. A high affinity binder could be identified from the combinatorial library for example by using an inhibition assay, in which the library compounds are used to inhibit the bacterial binding to the glycolipids or glycoconjugates described by the invention. Structural analogs and derivatives

preferred according to the invention can inhibit the binding of the *Helicobacter pylori* binding oligosaccharide sequences according to the invention to *Helicobacter pylori*.

5 Steric hindrance by the lipid part or the proximity of the silica surface probably limits the measurement of the epitope GlcNAc $\beta$ 3Gal $\beta$ 4Glc in current TLC-assay. Using the assay activity of this sequence could not be obtained in recent study of toxin A from *Clostridium difficile*, which specifically recognizes the same four trisaccharide epitopes described here for *Helicobacter pylori* (Teneberg *et al.*, 1996). However, the binding of Gal $\alpha$ 3Gal $\beta$ 4Glc to the toxin A was demonstrated by others using a large polymeric spacer modified conjugate  
10 of the saccharide (Castagliuolo *et al.*, 1996). Also considering the contribution of the terminal monosaccharide to the binding indicates that Glc could be allowed at the reducing end of the epitope; in the non-active N-deacetylated form the positive charge of the free amine group is probably more destructive to the binding than the presence of the hydroxyl group. The trisaccharide epitopes with Glc at reducing end are considered as effective  
15 analogs of the *Helicobacter pylori* binding substance when present in oligovalent or more preferably in polyvalent form. One embodiment of the present invention is the saccharides with Glc at reducing end, which are used as free reducing saccharides with high concentration, preferably in the range 1 – 100 g/l, more preferably 1 – 20 g/l. It is realized that these saccharides may have minor activity in the concentration range 0,1 – 1 g/l.

20 In the following the *Helicobacter pylori* binding sequence is described as an oligosaccharide sequence. The oligosaccharide sequence defined here can be a part of a natural or synthetic glycoconjugate or a free oligosaccharide or a part of a free oligosaccharide. Such oligosaccharide sequences can be bonded to various monosaccharides or oligosaccharides or  
25 polysaccharides on polysaccharide chains, for example, if the saccharide sequence is expressed as part of a bacterial polysaccharide. Moreover, numerous natural modifications of monosaccharides are known as exemplified by O-acetyl or sulphated derivative of oligosaccharide sequences. The *Helicobacter pylori* binding substance defined here can comprise the oligosaccharide sequence described as a part of a natural or synthetic  
30 glycoconjugate or a corresponding free oligosaccharide or a part of a free oligosaccharide. The *Helicobacter pylori* binding substance can also comprise a mix of the *Helicobacter pylori* binding oligosaccharide sequences.

35 Several derivations of the receptor oligosaccharide sequence reduced the binding below the limit of detection in current assay, showing the specificity of the recognition. The binding data shows that if the said oligosaccharide sequences have GalNAc $\beta$ 3 linked to Gal $\alpha$ 3Gal $\beta$ 4GlcNAc (substituted sequence: GalNAc $\beta$ 3Gal $\alpha$ 3Gal $\beta$ 4GlcNAc), or Neu5Ac $\alpha$ 3 linked to GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc (substituted sequence:

Neu5Ac $\alpha$ 3GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc) the compounds are not active. When the said oligosaccharide sequence is Gal $\beta$ 4GlcNAc, it is not  $\alpha$ 4-galactosylated (sequence is not Gal $\alpha$ 4Gal $\beta$ 4GlcNAc),  $\alpha$ 3-, or  $\alpha$ 6-sialylated (sequence is not Neu5Ac $\alpha$ 3/6Gal $\beta$ 4GlcNAc),  $\alpha$ 2- or  $\alpha$ 3-fucosylated [said oligosaccharide sequence is not Fuca $\alpha$ 2Gal $\beta$ 4GlcNAc or Gal $\beta$ 4(Fuca $\alpha$ 3)GlcNAc or Fuca $\alpha$ 2Gal $\beta$ 4(Fuca $\alpha$ 3)GlcNAc,  $\alpha$ 3-fucosylation referring to fucosylation of GlcNAc residues of lactosamine forming Lewis x, Gal $\beta$ 4(Fuca $\alpha$ 3)GlcNAc]. Saccharides having structures where Gal $\beta$ 3 is linked to GlcNAc $\beta$ 3 (such as Gal $\beta$ 3GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc/Glc) have different conformations in comparison to the *Helicobacter pylori* binding substances described herein and their binding specificities have been studied separately. The *Helicobacter pylori* binding substances may be part of a saccharide chain or a glycoconjugate or a mixture of glycocompounds containing other known *Helicobacter* binding epitopes, with different saccharide sequences and conformations, such as Lewis b (Fuca $\alpha$ 2Gal $\beta$ 3(Fuca $\alpha$ 4)GlcNAc) or Neu5Ac $\alpha$ 3Gal $\beta$ 4Glc/GlcNAc. Using several binding substances together may be beneficial for therapy.

The *Helicobacter pylori* binding oligosaccharide sequences can be synthesized enzymatically by glycosyltransferases, or by transglycosylation catalyzed by glycosidase or transglycosidase enzymes (Ernst *et al.*, 2000). Specificities of these enzymes and the use of co-factors can be engineered. Specific modified enzymes can be used to obtain more effective synthesis, for example, glycosynthase is modified to do transglycosylation only. Organic synthesis of the saccharides and the conjugates described herein or compounds similar to these are known (Ernst *et al.*, 2000). Saccharide materials can be isolated from natural sources and modified chemically or enzymatically into the *Helicobacter pylori* binding compounds. Natural oligosaccharides can be isolated from milks produced by various ruminants. Transgenic organisms, such as cows or microbes, expressing glycosylating enzymes can be used for the production of saccharides.

The uronic acid monosaccharide residues described in the invention can be obtained by methods known in the art. For example, the hydroxyl of the 6-carbon of N-acetylglucosamine or N-acetylgalactosamines can be chemically oxidized to carboxylic acid. The oxidation can be done to a properly protected oligosaccharide or monosaccharide.

In a preferred embodiment a non-protected polymer or oligomer comprising hexoses, N-acetylhexosamines or hexosamines, wherein the linkage between the monosaccharides is not between carbon 6 atoms, is

- 1) oxidized to corresponding polymer of uronic acid residues, or to polymer comprising monomers of 6-aldehydomonosaccharides
- 2) optionally derivatized from the carboxylic acid group or 6-aldehyde group, preferentially to an amide or an amine and
- 5 3) hydrolysed to the uronic acid monosaccharides or uronic acid derivative monosaccharides.

Methods to oxidize monosaccharide residues to uronic acids and to hydrolyse amine or uronic acid polymers chemically or enzymatically are well-known in the art. It is especially preferred to use the method to oligomers or polymers of cellulose, starch or other glucans with 1-2 or 1-3 or 1-4 linkages, chitin (GlcNAc polymer) or chitosan (GlcN polymer), which are commercially available in large scale or N-acetylgalactosamine/galactosamine polysaccharides (for example, ones known from a bacterial source) is oxidized to a corresponding 1-4-linked saccharide. This

10 method can also be applied to galactan polymers. Derivatives of uronic acid can be produced also from natural polymers comprising uronic acids such as pectins or glucuronic acid containing bacterial polysaccharides including N-acetylheparin, hyaluronic and chondroitin type bacterial exopolysaccharides. This method involves

- 1) derivatization of the carboxylic acid groups of the polysaccharide, preferably
- 20 by an amide bond and
- 2) hydrolysis of the polysaccharide to the uronic acid monosaccharides or uronic acid derivative monosaccharides.

Chemical and enzymatic methods are also known to oxidize primary alcohol on carbon 6 of the polysaccharide to aldehyde or to carboxylic acid. An aldehyde can be further derivatized, for example, to amine by reductive amination. Preferably terminal Gal or GalNAc is oxidized by a primary alcohol oxidizing enzyme-like galactose oxidase and can then be further derivatized, for example, by amines.

25

30 The uronic acid residues can be conjugated to disaccharides or oligosaccharides by standard methods of organic chemistry. Alternatively GlcA can be linked by a glucuronyl transferase transferring a GlcA from UDP-GlcA to terminal Lac(NAc).

Monosaccharide derivatives mimicking N-acetylhexosamines could be produced from a polymer or an oligomer comprising hexosamines or other monosaccharides with free primary amine groups by method involving:

- 1) derivatization of the amine groups to a secondary or tertiary amine or amide
- 5 2) hydrolysing the polymer to corresponding monosaccharides.

Chitosan and oligosaccharides thereof are an example of an amine comprising polymer or oligomer.


- 10 In general the method to produce carboxylic acid containing, 6-aldehydo comprising, amine and/or amide comprising monosaccharide/monosaccharides involves following steps
  1. optionally introducing an carboxylic acid or 6-aldehydo group to a carbohydrate polymer wherein primary hydroxyl is available for modification
  - 15 2. derivatization of carboxylic acid groups or 6-aldehydo groups or primary amine groups of the polymer to secondary or tertiary amines or to amides, when step 1 is applied, step 2 is optional.
  3. hydrolysis of the polymer to corresponding monosaccharides.
- 20 The hydrolysis to monosaccharides may also be partial and produce useful disaccharide or oligosaccharide to produce analog substances. Preferably the hydrolysis produces at least 30 % of monosaccharides. Methods to produce the chemical steps are known in the art. For example oxidation of the polysaccharides to corresponding monoaccharides can be performed as described by Muzzarelli et al
- 25 1999 and 2002. These methods are preferred to the use of non-protected monosaccharides, because the protection or reactive reducing ends of the monosaccharides is avoided.

In a preferred embodiment the oligosaccharide sequences comprising GlcA $\beta$ 3Lac or  
30 GlcA $\beta$ 3LacNAc are effectively synthesised by transglycosylation using a specific glucuronidase such as glucuronidase from bovine liver. It was realized that the enzyme can site-specifically transfer from  $\beta$ 1-3 linkage to Gal $\beta$ 4GlcNAc and Gal $\beta$ 4Glc with unexpectedly high yields for a transglycosylation reaction. In general



such selectivity and yields close 30 % or more are not obtained in transglycosylation reactions.

One embodiment of the present invention is use of a substance or a receptor binding  
5 to *Helicobacter pylori* comprising the oligosaccharide sequence



wherein q, r, s, t, and u are each independently 0 or 1,  
10

so that when t = 0 and u = 0, then the oligosaccharide sequence is linked to a  
polyvalent carrier or present as a free oligosaccharide in high concentration, and  
analogous or derivatives of said oligosaccharide sequence having binding activity to  
*Helicobacter pylori* for the production of a composition having *Helicobacter pylori*  
15 binding or inhibiting activity.

A in the above oligosaccharide sequence indicates uronic acid of the  
monosaccharide residue or carbon 6 derivative of the monosaccharide residue, most  
preferably the derivative of carbon 6 is an amide of the uronic acid.

20 The following oligosaccharide sequences are among the preferable *Helicobacter pylori* binding substances for the uses of the invention

Gal $\beta$ 4GlcNAc,

25 GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc, GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc, GlcNAc $\alpha$ 3Gal $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc, Gal $\alpha$ 3Gal $\beta$ 4GlcNAc, Gal $\beta$ 3Gal $\beta$ 4GlcNAc, Glc $\alpha$ 3Gal $\beta$ 4GlcNAc,  
Glc $\beta$ 3Gal $\beta$ 4GlcNAc,

30 Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc, Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,

GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,  
GlcNAc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,  
Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, Gal $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,  
35 Glc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, Glc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,

GalANAc $\beta$ 3Gal $\beta$ 4GlcNAc, GalANAc $\alpha$ 3Gal $\beta$ 4GlcNAc, GalA $\beta$ 3Gal $\beta$ 4GlcNAc,  
GalA $\alpha$ 3Gal $\beta$ 4GlcNAc, GalANAc $\beta$ 3Gal $\beta$ 4Glc, GalANAc $\alpha$ 3Gal $\beta$ 4Glc, GalA $\beta$ 3Gal $\beta$ 4Glc,  
GalA $\alpha$ 3Gal $\beta$ 4Glc,

- 5 GlcANAc $\beta$ 3Gal $\beta$ 4GlcNAc, GlcANAc $\alpha$ 3Gal $\beta$ 4GlcNAc, GlcA $\beta$ 3Gal $\beta$ 4GlcNAc,  
GlcA $\alpha$ 3Gal $\beta$ 4GlcNAc, GlcANAc $\beta$ 3Gal $\beta$ 4Glc, GlcANAc $\alpha$ 3Gal $\beta$ 4Glc, GlcA $\beta$ 3Gal $\beta$ 4Glc,  
GlcA $\alpha$ 3Gal $\beta$ 4Glc,

Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, and reducing-end polyvalent conjugates  
10 thereof,

as well as GalNAc $\alpha$ 3Gal $\beta$ 4Glc, GalNAc $\beta$ 3Gal $\beta$ 4Glc, GlcNAc $\alpha$ 3Gal $\beta$ 4Glc,  
GlcNAc $\beta$ 3Gal $\beta$ 4Glc, Gal $\alpha$ 3Gal $\beta$ 4Glc, Gal $\beta$ 3Gal $\beta$ 4Glc, Glc $\alpha$ 3Gal $\beta$ 4Glc, and  
Glc $\beta$ 3Gal $\beta$ 4Glc.


15

Another embodiment of the invention is described in Formula 1.

Formula 1:

20

25



A-saccharide

B-saccharide

- Among the preferable *Helicobacter pylori* binding substances or mixtures of the  
substances of the invention and for the uses of the invention are the oligosaccharide  
30 structures according to Formula 1, wherein integers l, m, and n have values  $m \geq 1$ , l  
and n are independently 0 or 1, and wherein R<sub>1</sub> is H and R<sub>2</sub> is OH or R<sub>1</sub> is OH and  
R<sub>2</sub> is H or R<sub>1</sub> is H and R<sub>2</sub> is a monosaccharidyl- or oligosaccharidyl- group  
preferably a beta glycosidically linked galactosyl group, R<sub>3</sub> is independently -OH or  
acetamido (-NHCOCH<sub>3</sub>) or an acetamido analogous group. R<sub>7</sub> is acetamido (-  
35 NHCOCH<sub>3</sub>) or an acetamido analogous group. When l = 1, R<sub>4</sub> is -H and R<sub>5</sub> is  
oxygen linked to bond R<sub>6</sub> and forms a beta anomeric glycosidic linkage to  
saccharide B or R<sub>5</sub> is -H and R<sub>4</sub> is oxygen linked to bond R<sub>6</sub> and forms an alpha

anomeric glycosidic linkage to saccharide B, when  $l = 0$   $R_6$  is -OH linked to B. X is monosaccharide or oligosaccharide residue, preferably X is lactosyl-, galactosyl-, poly-N-acetyl-lactosaminyl, or part of an O-glycan or an N-glycan oligosaccharide sequence; Y is a spacer group or a terminal conjugate such as a ceramide lipid moiety or a linkage to Z. Z is an oligovalent or a polyvalent carrier. The binding substance may also be an analog or derivative of said substance according to Formula 1 having binding activity with regard to *Helicobacter pylori*, e.g., the oxygen linkage (-O-) between position C1 of the B saccharide and saccharide residue X or spacer group Y can be replaced by carbon (-C-), nitrogen (-N-) or sulphur (-S-) linkage.

In Formula 1  $R_8$  is preferably carboxylic acid amide, such as methylamide or ethylamide, hydroxymethyl (-CH<sub>2</sub>-OH) or a carboxylic acid group or an ester thereof, such as methyl or ethyl ester. The carboxylic acid amide may comprise an alternative linkage to the polyvalent carrier Z comprising an amine such as chitosan or galactosamine polysaccharide or Z comprising a primary amine containing spacer, preferably a hydrophilic spacer. The structure in  $R_8$  can be also a mimicking structure known in the art to ones described above. For example secondary or tertiary amines or amidated secondary amine can be used.

In Formula 1  $R_9$  is preferably hydroxymethyl but it can be used for derivatisations as described for  $R_8$ .

$R_3$  is hydroxyl, acetamido or acetamido group mimicking group, such as C<sub>1-6</sub> alkyl-amides, arylamido, secondary amine, preferentially N-ethyl or N-methyl, O-acetyl, or O-alkyl for example O-ethyl or O-methyl.  $R_7$  is same as  $R_3$  but more preferentially acetamido or acetamido mimicking group.

$R_2$  may also comprise preferentially a six-membered ring structure mimicking Gal $\beta$ 4- terminal.

The bacterium binding substances are preferably represented in clustered form such as by glycolipids on cell membranes, micelles, liposomes, or on solid phases such as TCL-plates used in the assays. The clustered representation with correct spacing creates high affinity binding.

According to the invention it is also possible to use the *Helicobacter pylori* binding epitopes or naturally occurring, or a synthetically produced analogue or derivative

- thereof having a similar or better binding activity with regard to *Helicobacter pylori*. It is also possible to use a substance containing the bacterium binding substance such as a receptor active ganglioside described in the invention or an analogue or derivative thereof having a similar or better binding activity with regard to
- 5 *Helicobacter pylori*. The bacterium binding substance may be a glycosidically linked terminal epitope of an oligosaccharide chain. Alternatively the bacterium binding epitope may be a branch of an oligosaccharide chain, preferably a polylactosamine chain.
- 10 The *Helicobacter pylori* binding substance may be conjugated to an antibiotic substance, preferably a penicillin type antibiotic. The *Helicobacter pylori* binding substance targets the antibiotic to *Helicobacter pylori*. Such conjugate is beneficial in treatment because a lower amount of antibiotic is needed for treatment or therapy against *Helicobacter pylori*, which leads to lower side effect of the antibiotic. The
- 15 antibiotic part of the conjugate is aimed at killing or weaken the bacteria, but the conjugate may also have an antiadhesive effect as described below.
- The bacterium binding substances, preferably in oligovalent or clustered form, can be used to treat a disease or condition caused by the presence of the *Helicobacter*
- 20 *pylori*. This is done by using the *Helicobacter pylori* binding substances for anti-adhesion, i.e. to inhibit the binding of *Helicobacter pylori* to the receptor epitopes of the target cells or tissues. When the *Helicobacter pylori* binding substance or pharmaceutical composition is administered it will compete with receptor glycoconjugates on the target cells for the binding of the bacteria. Some or all of the
- 25 bacteria will then be bound to the *Helicobacter pylori* binding substance instead of the receptor on the target cells or tissues. The bacteria bound to the *Helicobacter pylori* binding substances are then removed from the patient (for example by the fluid flow in the gastrointestinal tract), resulting in reduced effects of the bacteria on the health of the patient. Preferably the substance used is a soluble composition
- 30 comprising the *Helicobacter pylori* binding substances. The substance can be attached to a carrier substance which is preferably not a protein. When using a carrier molecule several molecules of the *Helicobacter pylori* binding substance can be attached to one carrier and inhibitory efficiency is improved.
- 35 The target cells are primarily epithelial cells of the target tissue, especially the gastrointestinal tract, other potential target tissues are for example liver and pancreas. Glycosylation of the target tissue may change because of infection by a pathogen (Karlsson *et al.*, 2000). Target cells may also be malignant, transformed or

cancer/tumour cells in the target tissue. Transformed cells and tissues express altered types of glycosylation and may provide receptors to bacteria. Binding of lectins or saccharides (carbohydrate-carbohydrate interaction) to saccharides on glycoprotein or glycolipid receptors can activate cells, in case of cancer/malignant cells this may

5 be lead to growth or metastasis of the cancer. Several of the oligosaccharide epitopes described herein, such as GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc (Hu, J. *et al.*, 1994), Gal $\alpha$ 3Gal $\beta$ 4GlcNAc (Castronovo *et al.*, 1989), and neutral and sialylated polylectosamines from malignant cells (Stroud *et al.*, 1996), have been reported to be cancer-associated or cancer antigens. Oligosaccharide chains containing

10 substances described herein have also been described from lymphocytes (Vivier *et al.*, 1993). *Helicobacter pylori* is associated with gastric lymphoma. The substances described herein can be used to prevent binding of *Helicobacter pylori* to premalignant or malignant cells and activation of cancer development or metastasis. Inhibition of the binding may cure gastric cancer, especially lymphoma. The

15 *Helicobacter pylori* binding oligosaccharide sequence has been reported in the structure GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6GalNAc from human gastric mucins. This mucin epitope and similar O-glycan glycoforms are most probably natural high affinity receptors for *Helicobacter pylori* in human stomach. This was also indicated by high affinity binding of an analogous sequence

20 GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6GlcNAc as neoglycolipid to *Helicobacter pylori* and that the sequence GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6Gal has also some binding activity towards *Helicobacter pylori* in the same assay. Therefore the preferred oligosaccharide sequences includes O-glycans and analogues of O-glycan sequences such as GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6GlcNAc/GalNAc/Gal,

25 GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6GlcNAc/GalNAc/Gal $\alpha$ Ser/Thr, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6(Gal/GlcNAc $\beta$ 3)GlcNAc/GalNAc/Gal $\alpha$ Ser/Thr and glycopeptides and glycopeptide analogs comprising the O-glycan sequences. Even sequences lacking the non-reducing end GlcNAc may have some activity. Based on this all the other *Helicobacter pylori* binding oligosaccharide sequences (OS) and

30 especially the trisaccharide epitopes are also especially preferred when linked from the reducing end to form structures OS $\beta$ 6Gal(NAc)<sub>0-1</sub> or OS $\beta$ 6Glc(NAc)<sub>0-1</sub> or OS $\beta$ 6Gal(NAc)<sub>0-1</sub> $\alpha$ Ser/Thr or OS $\beta$ 6Glc(NAc)<sub>0-1</sub> $\alpha$ Ser/Thr. The Ser or Thr-compounds or analogue thereof or the reducing oligosaccharides are also preferred

when linked to polyvalent carrier. The reducing oligosaccharides can be reductively linked to the polyvalent carrier.

- Target cells also includes blood cells, especially leukocytes. It is known that
- 5 *Helicobacter pylori* strains associated with peptic ulcer, as the strain mainly used here, stimulates an inflammatory response from granulocytes, even when the bacteria are nonopsonized (Rautelin *et al.*, 1994a,b). The initial event in the phagocytosis of the bacterium most likely involves specific lectin-like interactions resulting in the agglutination of the granulocytes (Ofek and Sharon, 1988).
- 10 Subsequent to the phagocytotic event oxidative burst reactions occur which may be of consequence for the pathogenesis of *Helicobacter pylori*-associated diseases (Babior, 1978). Several sialylated and non-acid glycosphingolipids having repeating N-acetylglucosamine units have been isolated and characterized from granulocytes (Fukuda *et al.*, 1985; Stroud *et al.*, 1996) and may thus act as potential receptors for
- 15 *Helicobacter pylori* on the white blood cell surface. Furthermore, also the X<sub>2</sub> glycosphingolipid has been isolated from the same source (Teneberg, S., unpublished). The present invention confirms the presence of receptor saccharides on human erythrocytes and granulocytes which can be recognized by an N-acetylglucosamine specific lectin and by a monoclonal antibody (X<sub>2</sub>,
- 20 GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc-). The *Helicobacter pylori* binding substances can be useful to inhibit the binding of leukocytes to *Helicobacter pylori* and in prevention of the oxidative burst and/or inflammation following the activation of leukocytes.

- It is known that *Helicobacter pylori* can bind several kinds of oligosaccharide
- 25 sequences. Some of the binding by specific strains may represent more symbiotic interactions which do not lead to cancer or severe conditions. The present data about binding to cancer-type saccharide epitopes indicates that the *Helicobacter pylori* binding substance can prevent more pathologic interactions, in doing this it may leave some of the less pathogenic *Helicobacter pylori* bacteria/strains binding to
- 30 other receptor structures. Therefore total removal of the bacteria may not be necessary for the prevention of the diseases related to *Helicobacter pylori*. The less pathogenic bacteria may even have a probiotic effect in the prevention of more pathogenic strains of *Helicobacter pylori*.

- 35 It is also realized that *Helicobacter pylori* contains large polylactosamine oligosaccharides on its surface which at least in some strains contains non-fucosylated epitopes which can be bound by the bacterium as described by the invention. The substance described herein can also prevent the binding between

*Helicobacter pylori* bacteria and that way inhibit bacteria for example in process of colonization.

According to the invention it is possible to incorporate the *Helicobacter pylori* binding substance, optionally with a carrier, in a pharmaceutical composition, which is suitable for the treatment of a condition due to the presence of *Helicobacter pylori* in a patient or to use the *Helicobacter pylori* binding substance in a method for treatment of such conditions. Examples of conditions treatable according to the invention are chronic superficial gastritis, gastric ulcer, duodenal ulcer, non-Hodgkin lymphoma in human stomach, gastric adenocarcinoma, and certain pancreatic, skin, liver, or heart diseases, sudden infant death syndrome, autoimmune diseases including autoimmune gastritis and pernicious anaemia and non-steroid anti-inflammatory drug (NSAID) related gastric disease, all, at least partially, caused by the *Helicobacter pylori* infection.

The pharmaceutical composition containing the *Helicobacter pylori* binding substance may also comprise other substances, such as an inert vehicle, or pharmaceutically acceptable carriers, preservatives etc, which are well known to persons skilled in the art. The *Helicobacter pylori* binding substance can be administered together with other drugs such as antibiotics used against *Helicobacter pylori*.

The *Helicobacter pylori* binding substance or pharmaceutical composition containing such substance may be administered in any suitable way, although an oral administration is preferred.

The term "treatment" used herein relates both to treatment in order to cure or alleviate a disease or a condition, and to treatment in order to prevent the development of a disease or a condition. The treatment may be either performed in an acute or in a chronic way.

The term "patient", as used herein, relates to any human or non-human mammal in need of treatment according to the invention.

It is also possible to use the *Helicobacter pylori* binding substance to identify one or more adhesins by screening for proteins or carbohydrates (by carbohydrate-carbohydrate interactions) that bind to the *Helicobacter pylori* binding substance. The carbohydrate binding protein may be a lectin or a carbohydrate binding enzyme.

The screening can be done for example by affinity chromatography or affinity cross linking methods (Ilver *et al.*, 1998).

- Furthermore, it is possible to use substances specifically binding or inactivating the *Helicobacter pylori* binding substances present on human tissues and thus prevent the binding of *Helicobacter pylori*. Examples of such substances include plant lectins such as *Erythrina cristagalli* and *Erythrina corallodendron* (Teneberg *et al.*, 1994). When used in humans, the binding substance should be suitable for such use such as a humanized antibody or a recombinant glycosidase of human origin which is non-immunogenic and capable of cleaving the terminal monosaccharide residue/residues from the *Helicobacter pylori* binding substances. However, in the gastrointestinal tract, many naturally occurring lectins and glycosidases originating for example from food are tolerated.
- Furthermore, it is possible to use the *Helicobacter pylori* binding substance as part of a nutritional composition including food- and feedstuff. It is preferred to use the *Helicobacter pylori* binding substance as a part of so called functional or functionalized food. The said functional food has a positive effect on the person's or animal's health by inhibiting or preventing the binding of *Helicobacter pylori* to target cells or tissues. The *Helicobacter pylori* binding substance can be a part of a defined food or functional food composition. The functional food can contain other acceptable food ingredients accepted by authorities such as Food and Drug Administration in the USA. The *Helicobacter pylori* binding substance can also be used as a nutritional additive, preferably as a food or a beverage additive to produce a functional food or a functional beverage. The food or food additive can also be produced by having, e.g., a domestic animal such as a cow or other animal produce the *Helicobacter pylori* binding substance in larger amounts naturally in its milk. This can be accomplished by having the animal overexpress suitable glycosyltransferases in its milk. A specific strain or species of a domestic animal can be chosen and bred for larger production of the *Helicobacter pylori* binding substance. The *Helicobacter pylori* binding substance for a nutritional composition or nutritional additive can also be produced by a micro-organisms such as a bacteria or a yeast.
- It is especially useful to have the *Helicobacter pylori* binding substance as part of a food for an infant, preferably as a part of an infant formula. Many infants are fed by special formulas in replacement of natural human milk. The formulas may lack the special lactose based oligosaccharides of human milk, especially the elongated ones



such as lacto-N-neotetraose, Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, and its derivatives. The lacto-N-neotetraose and para-lacto-N-neohexaose (Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc) as well as Gal $\beta$ 3Gal $\beta$ 4Glc are known from human milk and can therefore be considered as safe additives or ingredients in an infant food. *Helicobacter pylori* is especially infective with regard to infants or young children, and considering the diseases it may later cause it is reasonable to prevent the infection. *Helicobacter pylori* is also known to cause sudden infant death syndrome, but the strong antibiotic treatments used to eradicate the bacterium may be especially unsuitable for young children or infants.

Preferred concentrations for human milk oligosaccharides in functional food to be consumed (for example, in reconstituted infant formula) are similar to those present in natural human milk. It is noted that natural human milk contains numerous free oligosaccharides and glycoconjugates (which may be polyvalent) comprising the oligosaccharide sequence(s) described by the invention, wherefore it is possible to use even higher than natural concentrations of single molecules to get stronger inhibitory effect against *Helicobacter pylori* without harmful side effects. Natural human milk contains lacto-N-neotetraose at least in range about 10 – 210 mg/l with individual variations (Nakhla *et al.*, 1999). Consequently, lacto-N-neotetraose is preferably used in functional food in concentration range 0,01 – 10 g/l, more preferably 0,01 – 5 g/l, most preferably 0,1 – 1 g/l. When the free oligosaccharides described herein are trisaccharides or the disaccharide with sequence Gal $\beta$ 4Glc at the reducing end, they are preferably consumed in concentrations 1 – 100 g/l, more preferably in the concentration range 1 – 20 g/l. Alternatively, the total concentration of the saccharides used in functional food is the same or similar to the total concentration of natural human milk saccharides, which bind *Helicobacter pylori* like the substances described, or which contain the binding epitope/oligosaccharide sequence indicated in the invention. At least in one case human milk has been reported to contain Gal $\beta$ 3Gal $\beta$ 4Glc as a major neutral oligosaccharide with high concentration (Charlwood *et al.*, 1999).

Furthermore, it is possible to use the *Helicobacter pylori* binding substance in the diagnosis of a condition caused by an *Helicobacter pylori* infection. Diagnostic uses also include the use of the *Helicobacter pylori* binding substance for typing of *Helicobacter pylori*. When the substance is used for diagnosis or typing, it may be included in, e.g., a probe or a test stick, optionally constituting a part of a test kit. When this probe or test stick is brought into contact with a sample containing

*Helicobacter pylori*, the bacteria will bind the probe or test stick and can be thus removed from the sample and further analyzed.

5 The results also show that the non-reducing end terminal monosaccharide residue in the preferred trisaccharide sequences of the invention can contain a carboxylic acid group on the carbon 6 (terminal monosaccharide residue is a uronic acid, HexA or HexANAc, wherein Hex is Gal or Glc) or a derivative of the carbon 6 of the HexA(NAc) residue or a derivative of the carbon 6 of the corresponding Hex(NAc) residue. Such terminal residues includes preferably  $\beta$ 3-linked glucuronic acid and  
10 more preferably 6-amides such as methylamide thereof. Therefore analogs and derivatives of the sequence can be produced by changing or derivatising the terminal 6-position of the trisaccharide epitopes.

#### **Preferred *Helicobacter pylori* binding substances**

15

The oligosaccharide sequences according to the invention were found to be unexpectedly effective binders when presented on thin layer surface. This method allows polyvalent presentation of the glycolipid sequences. The surprisingly high activity of the polyvalent presentation of the oligosaccharide sequences makes  
20 polyvalency a preferred way to represent the oligosaccharide sequences of the invention.

The glycolipid structures are naturally presented in a polyvalent form on cellular membranes. This type of representation can be mimicked by the solid phase assay  
25 described below or by making liposomes of glycolipids or neoglycolipids.

The present novel neoglycolipids produced by reductive amination of hydrophobic hexadecylaniline were able to provide effective presentation of the oligosaccharides. Most previously known neoglycolipid conjugates used for binding of bacteria have  
30 contained a negatively charged groups such as phosphor ester of phosphadityl ethanolamine neoglycolipids. Problems of such compounds are negative charge of the substance and natural biological binding involving the phospholipid structure. Negatively charged molecules are known to be involved in numerous non-specific bindings with proteins and other biological substances. Moreover, many of these  
35 structures are labile and can be enzymatically or chemically degraded. The present

invention is directed to the non-acidic conjugates of oligosaccharide sequences meaning that the oligosaccharide sequences are linked to non-acidic chemical structures. Preferably, the non-acidic conjugates are neutral meaning that the oligosaccharide sequences are linked to neutral, non-charged, chemical structures.

- 5 The preferred conjugates according to the invention are polyvalent substances.

In the previous art bioactive oligosaccharide sequences are often linked to carrier structures by reducing a part of the receptor active oligosaccharide structure.


- Hydrophobic spacers containing alkyl chains  $(-\text{CH}_2-)_n$  and/or benzyl rings have been  
10 used. However, hydrophobic structures are in general known to be involved in non-specific interactions with proteins and other bioactive molecules.

- The neoglycolipid data of the examples below show that under the experimental conditions used in the assay the hexadecylaniline parts of the neoglycolipid  
15 compounds do not cause non-specific binding for the studied bacterium. In the neoglycolipids the hexadecylaniline part of the conjugate forms probably a lipid layer like structure and is not available for the binding. The invention shows that reducing a monosaccharide residue belonging to the binding epitope may destroy the binding. It was further realized that a reduced monosaccharide can be used as a  
20 hydrophilic spacer to link a receptor epitope and a polyvalent presentation structure. According to the invention it is preferred to link the bioactive oligosaccharide via a hydrophilic spacer to a polyvalent or multivalent carrier molecule to form a polyvalent or oligovalent/multivalent structure. All polyvalent (comprising more than 10 oligosaccharide residues) and oligovalent/multivalent structures (comprising  
25 2-10 oligosaccharide residues) are referred here as polyvalent structures, though depending on the application oligovalent/multivalent constructs can be more preferred than larger polyvalent structures. The hydrophilic spacer group comprises preferably at least one hydroxyl group. More preferably the spacer comprises at least two hydroxyl groups and most preferably the spacer comprises at least three  
30 hydroxyl groups.

According to the invention the hydrophilic spacer group is preferably a flexible chain comprising one or several  $-\text{CHOH}-$  groups and/or an amide side chain such as an acetamido  $-\text{NHCOCH}_3$  or an alkylamido. The hydroxyl groups and/or the

acetamido group also protects the spacer from enzymatic hydrolysis in vivo. The term flexible means that the spacer comprises flexible bonds and do not form a ring structure without flexibility. A reduced monosaccharide residues such as ones formed by reductive amination in the present invention are examples of flexible hydrophilic spacers. The flexible hydrophilic spacer is optimal for avoiding non-specific binding of neoglycolipid or polyvalent conjugates. This is essential optimal activity in bioassays and for bioactivity of pharmaceuticals or functional foods, for example.

10 A general formula for a conjugate with a flexible hydrophilic linker has the following Formula 2:



15 wherein  $\text{L}_1$  and  $\text{L}_2$  are linking groups comprising independently oxygen, nitrogen, sulphur or carbon linkage atom or two linking atoms of the group forming linkages such as  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{CH}_2-$ ,  $-\text{N}-$ ,  $-\text{N}(\text{COCH}_3)-$ , amide groups  $-\text{CO}-\text{NH}-$  or  $-\text{NH}-\text{CO}-$  or  $-\text{N}-\text{N}-$  (hydrazine derivative) or amino oxy-linkages  $-\text{O}-\text{N}-$  and  $-\text{N}-\text{O}-$ .  $\text{L}_1$  is linkage from carbon 1 of the reducing end monosaccharide of X or when  $n=0$ ,  $\text{L}_1$  replaces  $-\text{O}-$  and links directly from the reducing end C1 of OS.

$p_1$ ,  $p_2$ ,  $p_3$ , and  $p_4$  are independently integers from 0-7, with the proviso that at least one of  $p_1$ ,  $p_2$ ,  $p_3$ , and  $p_4$  is at least 1.  $\text{CH}_{1-2}\text{OH}$  in the branching term  $\{\text{CH}_{1-2}\text{OH}\}_{p1}$  means that the chain terminating group is  $\text{CH}_2\text{OH}$  and when the  $p_1$  is more than 1 there is secondary alcohol groups  $-\text{CHOH}-$  linking the terminating group to the rest of the spacer. R is preferably acetyl group ( $-\text{COCH}_3$ ) or R is an alternative linkage to Z and then  $\text{L}_2$  is one or two atom chain terminating group, in another embodiment R is an analog forming group comprising  $\text{C}_{1-4}$  acyl group (preferably hydrophilic such as hydroxy alkyl) comprising amido structure or H or  $\text{C}_{1-4}$  alkyl forming an amine. And  $m > 1$  and Z is polyvalent carrier. OS and X are defined in Formula 1.

Preferred polyvalent structures comprising a flexible hydrophilic spacer according to formula 2 include *Helicobacter pylori* binding oligosaccharide sequence(OS)  $\beta 1-3$  linked to  $\text{Gal}\beta 4\text{Glc}(\text{red})-\text{Z}$ , and  $\text{OS}\beta 6\text{GlcNAc}(\text{red})-\text{Z}$  and  $\text{OS}\beta 6\text{GalNAc}(\text{red})-\text{Z}$ .,

where “(red)” means the amine linkage structure formed by reductive amination from the reducing end monosaccharides and an amine group of the polyvalent carrier Z.


- 5 In the present invention the oligosaccharide group is preferably linked in a polyvalent or an oligovalent form to a carrier which is not a protein or peptide to avoid antigenicity and possible allergic reactions, preferably the backbone is a natural non-antigenic polysaccharide.
- 10 When the binding activities of glycolipids and neoglycolipids were compared, the sequences with  $\text{Gal}\alpha 3\text{Gal}\beta$ - were found to have lower activity in the polyvalent presentation on thin layer plate. The sequences with terminal  $\text{Gal}\beta 4\text{GlcNAc}$ - sequence were also weaker. Therefore the optimal polyvalent non-acidic substance according to the invention comprises a terminal oligosaccharide sequence

15



- wherein  $q1$ ,  $q2$ ,  $r1$ ,  $r2$ , and  $u$  are each independently 0 or 1, with the proviso that when both  $q1$  and  $r1$  are 0, then the non-reducing end terminal
- 20 monosaccharide residue is not  $\text{Gal}\alpha$ . More preferably  $u=0$  and most preferably the oligosaccharide sequence presented in polyvalent form is  $\text{GalNAc/Glc(NAc)}_{r2}\alpha 3/\beta 3\text{Gal}\beta 4\text{GlcNAc}$  wherein  $r2$  is independently 0 or 1 and an analog or derivative thereof.

- 25 Following oligosaccharide sequences are especially preferred. These represent structures, which have not been described from human or animal tissues:



- with the proviso that when the oligosaccharide sequence contains  $\beta 3$  linkage,  $q$  and  $r$
- 30 are 1 or 0; or  $\text{GalA(NAc)}_r\alpha 3/\beta 3\text{Gal}\beta 4\text{Glc(NAc)}_u$ .

The novelty of the above oligosaccharide sequences makes them especially preferred. There are no known glycosidases cleaving such sequences. Therefore, the

sequences are especially stable and preferred under biological conditions. The natural type of the sequences described by the invention can be cleaved by glycosidase enzymes which reduces usefulness of these especially when used in human and animal body. Glycosidase enzymes cleaving the sequences are known to be active in human gastrointestinal tract. Several glycosidases such as N-acetylhexosaminidases or galactosidases has been described as digestive enzyme and are also present in food stuffs.

It is realized that the novel substances according to the invention are also useful for inhibiting toxin A of *Clostridium difficile* S. Teneberg et al 1996. The binding profile of the toxin A with older substances is very similar to specificity of *Helicobacter pylori* described here. Thus, the *Helicobacter pylori* binding substances may be used for the treatment, for example, *Clostridium difficile* dependent diarrhea.

Glycolipid and carbohydrate nomenclature is according to recommendations by the IUPAC-IUB Commission on Biochemical Nomenclature (Carbohydrate Res. 1998, 312, 167; Carbohydrate Res. 1997, 297, 1; Eur. J. Biochem. 1998, 257, 29).

It is assumed that Gal, Glc, GlcNAc, and Neu5Ac are of the D-configuration, Fuc of the L-configuration, and all the monosaccharide units in the pyranose form. Glucosamine is referred as GlcN or GlcNH<sub>2</sub> and galactosamine as GalN or GalNH<sub>2</sub>. Glycosidic linkages are shown partly in shorter and partly in longer nomenclature, the linkages of the Neu5Ac-residues  $\alpha 3$  and  $\alpha 6$  mean the same as  $\alpha 2-3$  and  $\alpha 2-6$ , respectively, and with other monosaccharide residues  $\alpha 1-3$ ,  $\beta 1-3$ ,  $\beta 1-4$ , and  $\beta 1-6$  can be shortened as  $\alpha 3$ ,  $\beta 3$ ,  $\beta 4$ , and  $\beta 6$ , respectively. Lactosamine refers to N-acetylglucosamine, Gal $\beta 4$ GlcNAc, and sialic acid is N-acetylneuraminic acid (Neu5Ac) or N-glycolylneuraminic acid (Neu5Gc) or any other natural sialic acid. Term glycan means here broadly oligosaccharide or polysaccharide chains present in human or animal glycoconjugates, especially on glycolipids or glycoproteins. In the shorthand nomenclature for fatty acids and bases, the number before the colon refers to the carbon chain length and the number after the colon gives the total number of double bonds in the hydrocarbon chain. Abbreviation GSL refers to glycosphingolipid. Abbreviations or short names or symbols of glycosphingolipids are given in the text and in Tables 1 and 2. *Helicobacter pylori* refers also to the bacteria similar to *Helicobacter pylori*.

In the present invention hex(NAc)-uronic acid and their derivatives and residues are indicated as follows: GlcA is glucuronic acid and derivatives of carbon 6 of glucose or glucuronic acid, GalA is galacturonic acid and derivatives of carbon 6 of galactose or galacturonic acid, GlcANAc is N-acetylglucuronic acid and derivatives of carbon 6 of N-acetylglucosamine or is N-acetylglucosamine uronic acid and GalANAc is N-acetylgalactosamine uronic acid and derivatives of carbon 6 of N-acetylgalactosamine or N-acetylgalactosamine uronic acid.

The expression "terminal oligosaccharide sequence" indicates that the oligosaccharide is not substituted to the non-reducing end terminal residue by another monosaccharide residue.

The term " $\alpha$ 3/ $\beta$ 3" indicates that the adjacent residues in an oligosaccharide sequence can be either  $\alpha$ 3- or  $\beta$ 3- linked to each other.

The present invention is further illustrated by the following examples, which in no way are intended to limit the scope of the invention:

## EXAMPLES

### Materials and methods

*Materials* - TLC silica gel 60 (aluminum) plates were from Merck (Darmstadt, Germany). All investigated glycosphingolipids were obtained in our laboratory.  $\beta$ -Galactosidase (*Escherichia coli*) was purchased from Boehringer Mannheim (Germany), Ham's F12 medium from Gibco (U.K.),  $^{35}$ S-methionine from Amersham (U.K.) and FCS (fetal calf serum) was from Sera-Lab (England).  $\beta$ 4-Galactosidase (*Streptococcus pneumoniae*),  $\beta$ -N-acetylhexosaminidase (*Streptococcus pneumoniae*) and sialidase (*Arthrobacter ureafaciens*) were from Oxford GlycoSystems (Abington, U.K.). The clinical isolates of *Helicobacter pylori* (strains 002 and 032) obtained from patients with gastritis and duodenal ulcer, respectively, were a generous gift from Dr. D. Danielsson, Örebro Medical Center, Sweden. Type strain 17875 was from Culture Collection, University of Göteborg (CCUG).

*Glycosphingolipids*. The pure glycosphingolipids of the experiment shown in Figs. 7A and 7B were prepared from total acid or non-acid fractions from the sources listed in Table 2 as described in (Karlsson, 1987). In general, individual glycosphingolipids were obtained by acetylation (Handa, 1963) of the total glycosphingolipid fractions and separated by repeated silicic acid column chromatography, and subsequently characterized structurally by mass spectrometry (Samuelsson *et al.*, 1990), NMR (Falk *et al.*, 1979a,b,c; Koerner Jr *et al.*, 1983)

and degradative procedures (Yang and Hakomori, 1971; Stellner *et al.*, 1973). Glycolipids derived from rabbit thymus are described below.

*Purification of glycolipids.* Acid glycosphingolipids were isolated from 1000 g acetone powder of rabbit thymus (Pel-Freeze Biological Inc., North Arkansas, Ark. US). The acetone powder was extracted in a Soxhlet apparatus with chloroform/methanol 2/1 (vol/vol unless otherwise stated) for 24 h followed by chloroform/methanol/water 8/1/1 for 36 h. The extracted lipids, 240 g, were subjected to Folch separation (Folch *et al.*, 1957) and the collected hydrophilic phase to ion-exchange gel chromatography on DE23 cellulose (DEAE, Whatman, Maidstone, UK). These isolation steps gave 2.5 g of acid glycosphingolipids. The gangliosides were separated according to number of sialic acids by ion-exchange gel with open-tubular chromatography on a glass column (50 mm i.d). The column was connected to an HPLC pump producing a concave gradient (pre-programmed gradient no 4, System Gold Chromatographic Software, Beckman Instruments Inc., CA, USA) starting with methanol and ending with 0.5 M CH<sub>3</sub>COONH<sub>4</sub> in methanol. The flow rate was 4 ml/min and 200 fractions with 8 ml in each were collected. 300-400 mg of ganglioside mixture was applied at a time to 500 g of DEAE Sepharose, (CL6, Pharmacia, Uppsala, Sweden, bed height approx. 130 mm). The monosialylated gangliosides were further separated by HPLC on a silica column, 300 mm x 22 mm i.d., 120 Å pore size, 10 µm particle size (SH-044-10, Yamamura Ltd., Kyoto, Japan). Approximately 150 mg of monosialylated gangliosides were applied at time and a straight eluting gradient was used (chloroform/methanol/water from 60/35/8 to 10/103, 4 ml/min, 240 fractions).

*Partial acid hydrolysis* - Desialylation of gangliosides was performed in 1.5% CH<sub>3</sub>COOH in water at 100°C after which the material was neutralized with NaOH and dried under nitrogen. For partial degradation of the carbohydrate backbone the glycolipid was hydrolyzed in 0.5M HCl for 7 min in a boiling water bath. The material was then neutralized and partitioned in C/M/H<sub>2</sub>O, (8:4:3, v/v)<sup>2</sup>. The lower phase was collected, evaporated under nitrogen and the recovered glycolipids were used for analysis.

*Preparation of pentaglycosylceramide from hexaglycosylceramide by enzyme hydrolysis* - Hexaglycosylceramide (structure 2, Table 1) obtained from heptaglycosylceramide (4 mg, from rabbit thymus) (structure 1, Table 1) by acidic desialylation (see above) was redissolved in C/M (2:1) and applied to a small silica gel column (0.4 x 5 cm). The column was eluted with C/M/H<sub>2</sub>O (60:35:8, v/v). Fractions of about 0.2 ml were collected and tested for the presence of carbohydrates. The recovered hexaglycosylceramide (2.0 mg) was dissolved in 1.5 ml of 0.1 M potassium phosphate buffer, pH 7.2, containing sodium taurodeoxycholate



(1.5 mg/ml),  $\text{MgCl}_2$  (0.001M) and  $\beta$ -galactosidase (*E. coli*, 500 U when assayed with 2-nitrophenyl- $\beta$ -D-galactoside as a substrate), and the sample was incubated overnight at 37°C. The material was next partitioned in C/M/ $\text{H}_2\text{O}$  (10:5:3) and the glycolipid contained in the lower phase was purified using silica gel

- 5 chromatography (0.4 x 5 cm columns) as described above for hexaglycosylceramide. To remove all contaminating detergent the chromatography was repeated twice. The final recovery of pentaglycosylceramide was 0.7 mg.

- Endoglycoceramidase digestion of glycolipids* (Ito and Yamagata, 1989) - The reaction mixture contained 200  $\mu\text{g}$  of glycolipid, 80  $\mu\text{g}$  of sodium taurodeoxycholate and 0.8 mU of enzyme in 160  $\mu\text{l}$  of 50 mM acetate buffer, pH 6.0. The sample was  
10 incubated overnight at 37°C, after which water (140  $\mu\text{l}$ ) and C/M, (2:1, by vol., 1500  $\mu\text{l}$ ) were added, and the sample was shaken and centrifuged. The upper phase was dried under nitrogen, redissolved in a small volume of water and desalted on a Sephadex G-25 column (0.4x10 cm), which had been equilibrated in  $\text{H}_2\text{O}$ , and  
15 eluted with water. Fractions of about 0.1 ml were collected and tested for the presence of sugars.

- Permethylation of saccharides* - Permethylation was performed according to Larson *et al.*, 1987. Sodium hydroxide was added to samples before methyl iodide as suggested by Needs and Selvendran 1993. In some experiments the saccharides were  
20 reduced with  $\text{NaBH}_4$  before methylation. In this case the amount of methyl iodide was increased to a final proportion of DMSO (dimethylsulfoxide)/methyl iodide of 1:1 (Hansson and Karlsson, 1990).

- Gas chromatography/mass spectrometry* - Gas chromatography was carried out on a Hewlett-Packard 5890A Series II gas chromatograph equipped with an on-  
25 column injector and a flame ionization detector. Permethylated oligosaccharides were analyzed on a fused silica capillary column (Fluka, 11m x 0.25 mm i.d.) coated with cross-linked PS264 (film thickness 0.03  $\mu\text{m}$ ). The sample was dissolved in ethyl acetate and injected on-column at 80°C. The temperature was programmed from 80°C to 390°C at a rate of 10°C/min with a 2 min hold at the upper  
30 temperature. Gas chromatography-mass spectrometry of the permethylated oligosaccharides was performed on a Hewlett-Packard 5890A Series II gas chromatograph interfaced to a JEOL SX-102 mass spectrometer (Hansson and Karlsson, 1990). FAB-MS analyses were performed on a JEOL SX-102 mass spectrometer. Negative FAB spectra were produced using Xe atom bombardment  
35 (10 kV) and triethanolamine as matrix.

*NMR spectroscopy* - Proton NMR spectra were recorded at 11.75 T on a Jeol Alpha 500 (Jeol, Tokyo, Japan) spectrometer. Samples were deuterium exchanged before analysis and

spectra were then recorded at 30 °C with a digital resolution of 0.35 Hz/pt. Chemical shifts are given relative to TMS (tetramethylsilane) using the internal solvent signal.

*Analytical enzymatic tests* - Oxford GlycoSystems enzymatic tests were performed according to the manufacturer's recommendations except that Triton X-100 was added to each incubation mixture to final concentration of 0.3%. When a mixture of sialidase and  $\beta$ 4-galactosidase were taken for digestion the incubation buffer from  $\beta$ 4-galactosidase kit was used. If  $\beta$ -hexosaminidase was present in the digestion mixture the buffer from this enzyme kit was employed. The enzyme concentrations in the incubation mixtures were: 80 mU/ml for Hex $\beta$ 4HexNAc-galactosidase (*S. pneumoniae*), 120 mU/ml for  $\beta$ -N-Acetylhexosaminidase (*S. pneumoniae*) and 1 U/ml for sialidase (*Arthrobacter ureafaciens*). The concentration of substrate was about 20  $\mu$ M. Enzymatic digestion was performed overnight at 37°C. After digestion the samples were dried and desalted using small columns of Sephadex G-25 (Wells and Dittmer, 1963), 0.3 g, equilibrated in C/M/H<sub>2</sub>O, (60:30:4.5, by vol.). Each sample was applied on the column in 2 ml of the same solvent and eluted with 2.5 ml of C/M/H<sub>2</sub>O, (60:30:4.5) and 2.5 ml of C/M, (2:1). Application and washing solutions were collected and evaporated under nitrogen.

*Other analytical methods* - Hexose was determined according to Dubois *et al.* 1956.

*De-N-acylation.* Conversion of the acetamido moiety of GlcNAc/GalNAc residues into an amine was accomplished by treating various glycosphingolipids with anhydrous hydrazine as described previously (Ångström *et al.*, 1998).

*Bacterial growth.* The *Helicobacter pylori* strains were stored at -80 °C in tryptic soy broth containing 15% glycerol (by volume). The bacteria were initially cultured on GAB-CAMP agar (Soltesz *et al.*, 1988) under humid (98%) microaerophilic conditions (O<sub>2</sub>: 5-7%, CO<sub>2</sub>: 8-10% and N<sub>2</sub>: 83-87%) at 37 °C for 48-72 h. For labeling colonies were inoculated on GAB-CAMP agar, except for the results presented in Figs. 1A and 1B where Brucella agar (Difco, Detroit, MI) was used instead, and 50  $\mu$ Ci <sup>35</sup>S-methionine (Amersham, U.K.), diluted in 0.5 ml phosphate-buffered saline (PBS), pH 7.3, was sprinkled over the plates. After incubation for 12-24 h at 37 °C under microaerophilic conditions, the cells were scraped off, washed three times with PBS, and resuspended to 1x10<sup>8</sup> CFU/ml in PBS. Alternatively, colonies were inoculated (1x10<sup>5</sup> CFU/ml) in Ham's F12 (Gibco BRL, U.K.), supplemented with 10% heat-inactivated fetal calf serum (Sera-Lab). For labeling, 50  $\mu$ Ci <sup>35</sup>S-methionine per 10 ml medium was added, and incubated with shaking under microaerophilic conditions for 24 h. Bacterial cells were harvested by centrifugation, and purity of the cultures and a low content of coccoid forms was ensured by phase-contrast microscopy. After two washes with PBS, the cells were resuspended to 1x10<sup>8</sup> CFU/ml in

PBS. Both labeling procedures resulted in suspensions with specific activities of approximately 1 cpm per 100 *Helicobacter pylori* organisms.

*TLC bacterial overlay assay.* Thin-layer chromatography was performed on glass- or aluminum-backed silica gel 60 HPTLC plates (Merck, Darmstadt, Germany) using  
5 chloroform/methanol/water 60:35:8 (by volume) as solvent system. Chemical detection was accomplished by anisaldehyde staining (Waldi, 1962). The bacterial overlay assay was performed as described previously (Hansson *et al.*, 1985). Glycosphingolipids (1-4 µg/lane, or as indicated in the figure legend) were chromatographed on aluminum-backed silica gel plates and thereafter treated with 0.3-0.5% polyisobutylmethacrylate in diethylether/*n*-  
10 hexane 1:3 (by volume) for 1 min, dried and subsequently soaked in PBS containing 2% bovine serum albumin and 0.1% Tween 20 for 2 h. A suspension of radio-labeled bacteria (diluted in PBS to  $1 \times 10^8$  CFU/ml and  $1-5 \times 10^6$  cpm/ml) was sprinkled over the chromatograms and incubated for 2 h followed by repeated rinsings with PBS. After drying the chromatograms were exposed to XAR-5 X-ray films (Eastman Kodak Co., Rochester,  
15 NY, USA) for 12-72 h.

*TLC protein overlay assays.*  $^{125}\text{I}$ -labeling of the monoclonal antibody TH2 and the lectin from *Erythrina cristagalli* (Vector Laboratories, Inc., Burlingame, CA) was performed by the Iodogen method (Aggarwal *et al.*, 1985), yielding an average of  $2 \times 10^3$  cpm/µg. The overlay procedure was the same as described above for bacteria except Tween was not used  
20 and that  $^{125}\text{I}$ -labeled protein, diluted to approximately  $2 \times 10^3$  cpm/µl with PBS containing 2% bovine serum albumin, was used instead of a bacterial suspension.

*Molecular modeling.* Minimum energy conformers of the glycosphingolipids listed in Table 1 were calculated within the Biograf molecular modeling program (Molecular Simulations Inc.) using the Dreiding-II force field (Mayo *et al.*, 1990) on a Silicon Graphics  
25 4D/35TG workstation. Partial atomic charges were generated using the charge equilibration method (Rappé and Goddard III, 1991), and a distance dependent dielectric constant ( $\epsilon=3.5r$ ) was used for the Coulomb interactions. In addition a special hydrogen bonding term was used in which the maximal interaction ( $D_{\text{hb}}$ ) was set to  $-4 \text{ kcal mol}^{-1}$ . The dihedral angles of the Glcβ1Cer linkage are defined as follows:  $\Phi = \text{H-1} - \text{C-1} - \text{O-1} - \text{C-1}$ ,  $\Psi = \text{C-1} - \text{O-1} - \text{C-1} - \text{C-2}$  and  $\theta = \text{O-1} - \text{C-1} - \text{C-2} - \text{C-3}$  starting from the glucose end (see Nyholm and  
30 Pascher, 1993).

The oligosaccharide GlcNAcβ3Galβ4GlcNAc was synthesised from Galβ4GlcNAc (Sigma, St. Louis, USA) and GlcNAcβ3Galβ4GlcNAcβ6GlcNAc was synthesised from  
35 Galβ4GlcNAcβ6GlcNAc by incubating the acceptor saccharide with human serum β3-N-acetylglucosaminyltransferase and UDP-GlcNAc in presence of 8 mM MnCl<sub>2</sub> and 0.2 mg/ml ATP at 37 degree of Celsius for 5 days in 50 mM TRIS-HCl pH 7.5. Galβ4GlcNAcβ6GlcNAc was obtained from GlcNAcβ6GlcNAc (Sigma, St Louis, USA) by

incubating the disaccharide with  $\beta$ 4Galactosyltransferase (bovine milk, Calbiochem., CA, USA) and UDP-Gal in presence of 20 mM  $\text{MnCl}_2$  for several hours in 50 mM MOPS-NaOH pH 7.4. Hexasaccharide  $\text{Gal}\beta 3\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}$  (1 mg, from Dextra labs, UK)) was treated with 400 mU  $\beta 3/6$ -galactosidase (Calbiochem., CA, USA) overnight as suggested by the producer. The oligosaccharides were purified chromatographically and their purity was assessed by MALDI-TOF mass spectrometry and NMR.

$\text{Gal}\alpha 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}$  was from Dextra laboratories, Reading, UK. The glycolipid  $\text{GlcA}\beta 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}\beta \text{Cer}$  (Wako Pure Chemicals, Osaka, Japan) was reduced to  $\text{Glc}\beta 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}\beta \text{Cer}$  as described in Lanne et al 1995. The glycolipid derivative  $\text{Glc(A-methylamide)}\beta 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}\beta \text{Cer}$  was produced by amidation of the carboxylic acid group of the glucuronic acid of  $\text{GlcA}\beta 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}\beta \text{Cer}$  as described in Lanne et al 1995.

## RESULTS

15

The heptaglycosylceramide

$\text{NeuGc}\alpha 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}\beta \text{Cer}$  was purified from rabbit thymus by HPLC as described above. The structure was characterized by NMR and mass spectrometry (data not shown). The heptasaccharide ganglioside was bound by most *Helicobacter pylori* isolates (about 60) tested in the laboratory of the inventors.

In order to detect possible minor isomeric components in the heptaglycosylceramide material, the ganglioside was desialylated, treated with endoglycoceramidase after which the released oligosaccharides were permethylated and analyzed by gas chromatography and EI/MS, (Figs. 1A and 1B). Two saccharides were identified in the six-sugar region which showed the expected carbohydrate sequence of Hex-HexNAc-Hex-HexNAc-Hex-Hex, as confirmed by fragment ions at  $m/z$  219, 464, 668, 913 and 1118. When the carbohydrates were converted to alditols (by reduction with  $\text{NaBH}_4$ ) before methylation distinct fragment ions at  $m/z$  235, 684 and 1133 were found in addition to the previously listed ions (data not shown). The predominant saccharide, which accounted for more than 90% of the total material (peak B, Figs. 1A and 1B), was characterized by a strong fragment ion at  $m/z$  182 confirming the presence of  $\beta 4\text{GlcNAc}$  (neolacto series, type 2 carbohydrate chain). The minor saccharide (peak A, Figs. 1A and 1B) gave a spectrum typical for type-1 chain (lacto series) with a very weak fragment ion at  $m/z$  182 and a strong fragment ion at  $m/z$  228. The preparation also contained traces of other sugar-positive substances which might be 4- and 5-sugar-containing saccharides of the same series. Fucose-containing saccharides were not found in the mixture. The purity of the asialoganglioside was tested also by FAB/MS and NMR

spectroscopy. The negative FAB/MS of the hexaglycosylceramide (Fig.2A) confirmed the predicted carbohydrate sequence and showed that the ceramides were composed mainly of sphingosine and C16:0 fatty acid ( $m/z$  536.5). The NMR spectrum obtained of hexaglycosylceramide (Fig. 3A) showed four major doublets in the anomeric region with  $\beta$ -couplings ( $J \sim 8$  Hz). They had an intensity ratio of 2:2:1:1. The signals at 4.655 ppm (GlcNAc $\beta$ 3), 4.256 ppm (internal Gal $\beta$ 4), 4.203 ppm (terminal Gal $\beta$ 4) and 4.166 ppm (Glc $\beta$ ) were in agreement with results previously published for nLcOse6-Cer (Clausen *et al.*, 1986). There was also a small doublet at 4.804 ppm, which together with a small methyl signal at 1.81 ppm (seen as a shoulder on the large type 2 methyl resonance) indicated the presence of a small fraction of type 1 chain. Due to the overlap in the 4.15 to 4.25 ppm region the position and distribution of this type 1 linkage could not be determined. The total amount of type 1 linkage was roughly 10%. As the amount of type 1 chain in the pentaglycosylceramide obtained from hexaglycosylceramide by  $\beta$ -galactosidase digestion also was approximately 5% (Fig 3B) it seems likely that the type 1 linkage was evenly distributed between the internal and external parts of the saccharide chain, i.e. 5% of the glycolipids could be type1-type1.

To find out if the binding activity of the glycolipid was associated with the predominant neolacto (type 2) structure the asialo-glycolipid was treated with  $\beta$ 4-galactosidase and  $\beta$ -hexosaminidase, and the products were investigated by TLC and by overlay tests (Figs. 4A, 4B and 4C). As expected, the first enzyme converted the hexaglycosylceramide to a pentaglycosylceramide (4A, lane 3) and the mixture of the two enzymes degraded the material to lactosylceramide (4B, lane 6). According to visual evaluation of the TLC plates both reactions were complete or almost complete. The same results were obtained for sialidase- and acid-treated material. The  $\beta$ 4-galactosidase degradation of hexaglycosylceramide was accompanied by disappearance of the *Helicobacter pylori* binding activity in the region of this glycolipid on TLC plates with simultaneous appearance of a strong activity in the region of pentaglycosylceramides (4C, lane 3). Further enzymatic degradation of the pentaglycosylceramide resulted in the disappearance of binding activity in this region. Appearance of binding activity in the four-sugar region was not observed. The sensitivity of the chemical staining of TLC plates is too low to allow trace substances to be observed.

In a separate experiment the parent ganglioside was subjected to partial acid degradation and the released glycolipids were investigated for *Helicobacter pylori* binding activity. Figs. 5A and 5B show TLC of the hydrolyzate (5A) and the corresponding autoradiogram (5B) after overlay of the hydrolyzate with  $^{35}\text{S}$ -labeled *Helicobacter pylori*. Glycolipids located in the regions of hexa-, penta-, tetra- and

diglycosylceramides displayed binding activity, whereas triglycosylceramide was inactive.

The binding of the hexa-, penta-, tetraglycosylceramides were similar when tested with at least three *Helicobacter pylori* strains (17875, 002 and 032).

- 5     The strongly binding pentaglycosylceramide produced after detachment of the terminal galactose from hexaglycosylceramide and purification by silica gel chromatography was investigated in greater detail. The negative ion FAB/MS spectrum of this glycolipid confirmed a carbohydrate sequence of HexNAc-Hex-HexNAc-Hex-Hex- and showed the same ceramide composition as the
- 10    hexaglycosylceramide (Fig 2B). The proton NMR spectrum obtained for the pentaglycosylceramide (Fig. 3B) had five major  $\beta$ -doublets in the anomeric region: at 4.653 ppm (internal GlcNAc $\beta$ 3), 4.615 ppm (terminal GlcNAc $\beta$ 3), 4.261 ppm (double intensity, internal Gal $\beta$ 4), 4.166 (Glc $\beta$ ), consistent with
- 15    GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer and also in perfect agreement with the six sugar compound having been stripped of its terminal Gal $\beta$ . There is also a small  $\beta$ -doublet at 4.787 ppm corresponding to 3-substituted GlcNAc $\beta$  (type 1 chain). The expected methyl signal was also seen as a shoulder on a much larger methyl signal at 1.82 ppm, but overlap prohibits quantitation of these signals. From the integral of the
- 20    anomeric proton it can be calculated that 6% of the glycolipid contained type 1 chain. Thus the relative proportion of type 2 and type 1 carbohydrate chains was similar to that of the six sugar glycolipid. The two spots visible on TLC plates both in the hexa- and pentaglycosyl fractions reflected a ceramide heterogeneity rather than differences in sugar chain composition as judged by their susceptibility to  $\beta$ 4-galactosidase. The upper penta-region spot appeared both after unselective
- 25    hydrolysis of the asialoganglioside and selective splitting of 4-linked galactose from the asialoprotein. Furthermore, when hexaglycosylceramide with a high content of the upper chromatographic subfraction was degraded by  $\beta$ 4-galactosidase and  $\beta$ -hexosaminidase the resulting lactosylceramide gave two distinct chromatographic bands. Chromatographically homogenous hexaglycosylceramide resulted in only one
- 30    lactosylceramide band. Both upper and lower subfractions in the penta-region were highly active as shown by overlay tests.

- 35    Glycosphingolipids of the neolacto series with 6, 5 and 4 sugars (structures 2, 4 and 5, Table I) were examined by semi-quantitative tests using the TLC overlay procedure. The glycolipids were applied on silica gel plates in series of dilutions and their binding to *Helicobacter pylori* was evaluated visually after overlay with labeled bacteria and autoradiography ( Figs. 6A and 6B). The most active species was pentaglycosylceramide, which gave a positive response on TLC plates in amounts down to 0.039 nmol/spot (mean value calculated from 7 experiments, standard

deviation  $\delta_{n-1} = 0.016$  nmol). Hexa- and tetraglycosylceramides bound *Helicobacter pylori* in amounts of c:a 0.2 and 0.3 nmoles of glycolipid/spot, respectively.

The binding of *Helicobacter pylori* to higher glycolipids of the investigated series was highly reproducible. The binding frequency for *Helicobacter pylori*, strain 032,  
 5 recorded for pentaglycosyl- and hexaglycosylceramides was ~ 90% (total number of plates was about 100).

*Binding assays revealing the isoreceptors and specificity of the binding (Figs. 7A and 7B.)*

In addition to the seven-sugar glycosphingolipid from rabbit thymus having a neolacto core,  
 10 NeuGc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, and tetra- to hexaglycosylceramides derived thereof, the binding specificity could involve other glycolipids from the neolacto series.

The binding of *Helicobacter pylori* (strain 032) to purified glycosphingolipids separated on thin-layer plates using the overlay assay is shown in Figs. 7A and 7B. These results  
 15 together with those from an additional number of purified glycosphingolipids are summarized in Table 2. The binding of *Helicobacter pylori* to neolactotetraosylceramide (lane 1) and the five- and six-sugar glycosphingolipids (lanes 5 and 6) derived from NeuGc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer is identical to results above. Unexpectedly, however, binding was also found for  
 20 GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer ( $x_2$  glycosphingolipid, lane 7) and the defucosylated A6-2 glycosphingolipid GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (no. 12, Table 2). Together with the finding that Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer (B5 glycosphingolipid, lane 2) also is binding-active, these results suggest the possibility of cross-binding rather than the presence of multiple adhesins specific for each of these  
 25 glycosphingolipids (see below). Furthermore, the only extension of the different five-sugar-containing glycosphingolipids just mentioned that was tolerated by the bacterial adhesin was Gal $\beta$ 4 to the thymus-derived GlcNAc $\beta$ 3-terminated compound (lane 6). Other elongated structures, as the NeuAc- $x_2$  (lane 8) and GalNAc $\beta$ 3-B5 (no. 25, Table 2), were thus all found to be non-binding. It may be further noticed that the acetamido group of the internal  
 30 GlcNAc $\beta$ 3 in B5 is essential for binding since de-*N*-acylation of this moiety by treatment with anhydrous hydrazine leads to complete loss of binding (lane 3) as is the case also when neolactotetraosylceramide is similarly treated (no. 6, Table 2).

*Cross-binding of five-sugar glycosphingolipids.* In order to understand the binding characteristics of the different neolacto-based glycosphingolipid molecules used in this study  
 35 the conformational preferences of active as well as inactive structures were investigated by molecular modeling. Figs. 8A, 8B, 8C and 8D show the  $x_2$  glycosphingolipid together with three other sequences: defucosylated A6-2, B5 and de-*N*-acylated B5, which, except for the chemically modified B5 structure, show similar binding strengths. Also the five-sugar

glycosphingolipid from rabbit thymus (see Fig. 9A) should be included in this comparison since this structure differs only at position four of the terminal residue compared with the  $x_2$  structure and is equally active. The four active structures all have neolacto cores which thus are terminated by GalNAc $\beta$ 3, GalNAc $\alpha$ 3, Gal $\alpha$ 3 and GlcNAc $\beta$ 3, respectively. The  
 5 minimum energy conformers of these structures were generated as described previously (Teneberg *et al.*, 1996). Other minimum energy structures given in Table 2 are based on earlier results found in the literature (Bock *et al.*, 1985; Meyer, 1990; Nyholm *et al.*, 1989). Regarding sialic acid-terminated glycosphingolipids the *synclinal* conformation was adopted for the glycosidic dihedral angles of  $\alpha$ 3-linked residues as seen in, e.g., Fig. 9C, but the  
 10 effect of other conformations (Siebert *et al.*, 1992), in particular the *anticlinal* one, was also tested. Also for the  $\alpha$ 6-linked variant several low energy conformers (Breg *et al.*, 1989) were generated for the same purpose.

As mentioned above, the fact that there are four binding-active five-sugar glycosphingolipids (nos. 10-13, Table 2), all having a neolacto core, suggests that cross-  
 15 binding to the same adhesin site may be the reason behind these observations. At first glance, however, it might seem surprising that the B5 glycosphingolipid, which differs at the terminal position in comparison with the five-sugar compound obtained from rabbit thymus, the former having a Gal $\alpha$ 3 and the latter a GlcNAc $\beta$ 3, is equally active and should be included within the binding specificity of the neolacto series. Despite the fact that these two  
 20 terminal saccharides differ also in their anomeric linkage it is seen (Figs. 8C and 9A) that the minimum energy structures topographically are very similar, the differences being that Gal $\alpha$ 3 lacks an acetamido group, has the 4-OH in the axial position and its ring plane raised slightly above the corresponding plane in the five-sugar compound. However, neither the 4-  
 OH position nor the absence/presence of an acetamido group appear to be crucial for binding  
 25 to occur, since also the  $x_2$  and defucosylated A6-2 glycosphingolipids (Fig. 8A, B), which are terminated by GalNAc $\beta$ 3 and GalNAc $\alpha$ 3, respectively, have similar affinities for the *Helicobacter pylori* adhesin. In the light of these findings also Gal $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, which has been isolated from human erythrocytes (Stellner and Hakomori, 1974), would be expected to bind the bacterial adhesin. In the light  
 30 of the rules of binding also three other terminal monosaccharides in *Helicobacter pylori* binding epitopes are possible trisaccharide binding epitopes, namely GlcNAc $\alpha$ 3Gal $\beta$ 4GlcNAc, Glc $\beta$ 3Gal $\beta$ 4GlcNAc and Glc $\alpha$ 3Gal $\beta$ 4GlcNAc. Such compounds are not known from human tissues so far, but could rather represent analogues of the natural receptor. Neither the Gal $\beta$ 3Gal $\beta$ 4GlcNAc-glycolipid nor the three analogs were  
 35 unfortunately available for testing.

The neolacto seven-sugar compound, NeuGc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, was also subjected to molecular modeling. Fig 10 shows two different projections of the



minimum energy structure with the Glc $\beta$ Cer linkage in an extended conformation. The sialic acid was given the *syn clinal* conformation but the *anti* conformer is also likely in unbranched structures (Siebert *et al.*, 1992). The sialic acid appears to have little influence on the binding activity towards *Helicobacter pylori* as compared with the six-sugar compound, 9B. Comparison of the first projection with Figs. 9A and 9B suggests that the same binding epitope is also available in the seven-sugar structure.

*Delineation of the neolacto binding epitope.* The relative binding strength of the structures obtained by chemical and enzymatic degradation of the rabbit thymus seven-sugar compound (nos. 1, 5, 10, and 21, Table 2) suggest that the three-sugar sequence GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3 may constitute the minimal binding sequence. Thus, in the six-sugar compound an inhibitory effect from the terminal Gal $\beta$ 4 is expected, whereas for neolactotetraosylceramide lack of a terminal GlcNAc $\beta$ 3 reduces the binding strength since only two out of three sugars in the epitope are present. The essentiality of the internal GlcNAc $\beta$ 3 is clearly shown by the loss of bacterial binding both to neolactotetraosylceramide and B5 following de-*N*-acylation of the acetamido group to an amine (nos. 6 and 14, Table 2). This non-binding may occur either by loss of a favorable interaction between the adhesin and the acetamido moiety and/or altered conformational preferences of these glycosphingolipids. However, it is difficult to envision a situation where an altered orientation of the internal Gal $\beta$ 4 would sterically hinder access to the binding epitope. Thus, having established that the minimal binding sequence must encompass the GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3 sequence it is now easy to rationalize the absence of binding for P<sub>1</sub>, H5-2 and the two sialylparagloboside structures (nos. 15, 18-20, Table 2) since these extensions interfere directly with the proposed binding epitope. Also the glycosphingolipid from bovine buttermilk (Teneberg *et al.*, 1994), which has a  $\beta$ 6-linked branch of Gal $\beta$ 4GlcNAc $\beta$  attached to the internal Gal $\beta$ 4 of neolactotetraosylceramide (no. 26, Table 2), is non-binding due to blocked access to the binding epitope.

Elongation of the different binding-active five-sugar sequences in Table 2 shows that only addition of Gal $\beta$ 4 to the thymus-derived structure is tolerated, in accordance with the observation that the 4-OH position may be either equatorial or axial, but with an ensuing loss of binding affinity due to steric interference. Addition of either NeuAc $\alpha$ 3 to x<sub>2</sub> or GalNAc $\beta$ 3 to B5 thus results in complete loss of binding (nos. 24 and 25, Table 2). It is further seen that the negative influence of a Fuc $\alpha$ 2 unit as in H5-2 is confirmed by the non-binding of *Helicobacter pylori* both to A6-2 and B6-2 (nos. 22 and 23, Table 2). Concerning the elongated structure (no. 28, Table 2), terminated by the same trisaccharide found in B5, it must, as in B5, be this terminal trisaccharide that is responsible for the observed binding although a second internal binding epitope also is present. However, binding to the internal epitope can most likely be excluded since the penultimate Gal $\beta$ 4 would be expected to

is obtained or not depends, however, both on the type of strain and growth conditions (Miller-Podraza *et al.*, 1996, 1997a,b).

To summarize, the binding epitope of the neolacto series of glycosphingolipids has to involve the three-sugar sequence GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3 in order to obtain maximal activity. From a comparison of the binding pattern of the potential isoreceptors used in this study it can be deduced from the structures shown in Figs. 8A-D and 9A-D that nearly all of this trisaccharide is important for binding to occur, excepting the acetamido group of the terminal GlcNAc $\beta$ 3 and the 4-OH on the same residue, which are non-crucial.

*Biological presence of the receptors.* Of the four five-sugar glycosphingolipids that *in vitro* may function interchangeably as receptors for *Helicobacter pylori* only x<sub>2</sub> occurs naturally in human tissue but has as yet not been found to be present in the gastric mucosa, excepting a case of gastric cancer where it was identified in the tumor tissue (Kannagi *et al.*, 1982b). A study by Thorn *et al.*, 1992, showed, however, that the x<sub>2</sub> glycosphingolipid and elongated structures having a terminal GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$  sequence are present in several human tissues, but gastric epithelial tissue was unfortunately not among the ones investigated. Thin-layer chromatogram overlay with the GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ -specific monoclonal antibody TH2 of preparations of total non-acid glycosphingolipids from epithelial cells of human gastric mucosa of several blood group A individuals (lanes 1-6) was therefore performed (Fig. 11B). No detectable binding, however, was observed to the glycosphingolipids derived from stomach epithelium using this assay. The corresponding overlay using the Gal $\beta$ 4GlcNAc-binding lectin from *E. cristagalli* is shown in Figs. 11A, 11B and 11C. Of the different glycosphingolipid preparations of gastric epithelial origin the first three lanes show weak binding to bands in the four-sugar region, which probably correspond neolactotetraosylceramide, but no detectable binding of *Helicobacter pylori* to these bands was discerned due to the low amounts of this glycosphingolipid (Teneberg *et al.*, 2001).

Furthermore, the sequence Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ , whether present in B5 glycosphingolipid or in the elongated structure discussed above (no. 28, Table 2), is possibly not found in normal human tissue due to non-expression of the transferase responsible for the addition of Gal $\alpha$ 3 (Larsen *et al.*, 1990). One is therefore left with the conclusion that if target receptor(s), carrying the binding epitope identified above, are present on the surface of the gastric epithelial cells they may be based on repetitive *N*-acetylglucosamine elements in glycoproteins and not on lipid-based structures.

However, it is known that *Helicobacter pylori* strains associated with peptic ulcer, as the strain mainly used here, stimulates an inflammatory response from granulocytes, even when the bacteria are nonopsonized (Rautelin *et al.*, 1994a,b). The initial event in the phagocytosis of the bacterium most likely involves specific lectin-like interactions resulting the agglutination of the granulocytes (Ofek and Sharon, 1988). Subsequent to the phagocytotic

event oxidative burst reactions occur which may be of consequence for the pathogenesis of *Helicobacter pylori*-associated diseases (Babior, 1978). Several acid and non-acid glycosphingolipids from granulocytes, having both a neolacto core and repeating lactosamine units, including no. 21 in Table 2 and the sialylated seven-sugar compound (no. 27, Table 2), where the acetamido group of the sialic acid is in the acetyl form, have been isolated and characterized (Fukuda *et al.*, 1985; Stroud *et al.*, 1996) and may thus act potential receptors for *Helicobacter pylori* on the white blood cell surface. Furthermore, also the x<sub>2</sub> glycosphingolipid has been isolated from the same source (Teneberg, S., unpublished).

Returning to Fig. 11B it is seen that the monoclonal antibody TH2 indeed binds to bands in the five-sugar region, both for granulocytes and erythrocytes (lanes 7 and 8, respectively), which may correspond to the x<sub>2</sub> glycosphingolipid (Teneberg, S., unpublished; Thorn *et al.*, 1992; Teneberg *et al.*, 1996). Similarly, neolactotetraosylceramide is found to be present both in granulocytes and erythrocytes when using the *E. cristagalli* lectin instead in the overlay assay (Fig. 11C, lanes 7 and 8). In these two cases *Helicobacter pylori* binds to neolactotetraosylceramide (Bergstöm, J., unpublished). For granulocytes a further rather weak band in the six-sugar region, probably corresponding to neolactotetraosylceramide extended by one *N*-acetylglucosamine unit (*cf.* no. 21, Table 2), is found in accordance with the results of Fukuda *et al.*, 1985. Whether these glycosphingolipids are prime targets in the agglutination process referred to above remains, however, to be elucidated.

#### *Analysis of neoglycolipids and novel glycolipids*

The oligosaccharides GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc,

GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6GlcNAc, Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc and

GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc and maltoheptaose (Sigma, Saint Louis, USA)

were reductively aminated with 4-hexadecylaniline (abbreviation HDA, from Aldrich, Stockholm, Sweden) by cyanoborohydride (Halina Miller-Podraza, to be published later). The products were characterized by mass spectrometry and were confirmed to be GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc(red)-HDA,

GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6GlcNAc(red)-HDA,

Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc(red)-HDA,

GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc(red)-HDA and maltoheptaose(red)-HDA

[where "(red)-" means the amine linkage structure formed by reductive amination from the reducing end glucoses of the saccharides and amine group of the

hexadecylaniline (HDA)]. The compounds Gal $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc(red)-HDA and GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc(red)-HDA had clear binding

activity and GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6GlcNAc(red)-HDA had strong binding activity with regard to *Helicobacter pylori* in TLC overlay assay described above, while the GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc(red)-HDA and maltoheptaose(red)-HDA were weakly binding or inactive. The example shows that the tetrasaccharide

- 5 GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal is a structure binding to *Helicobacter pylori*. The reducing end Glc-residue is probably not needed for the binding because the reduction destroys the pyranose ring structure of the Glc-residue. In contrast, the intact ring structure of reducing end GlcNAc is needed for good binding of the trisaccharide GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc.

10

The a biosynthetic precursor analog of NHK-1 glycolipid

GlcA $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer, and novel glycolipids

Glc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer and Glc(A-

methylamide) $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer were tested in TLC overlay assay

- 15 and were observed to be binding active with regard to *Helicobacter pylori*. Glc(A-methylamide) means glucuronic acid derivative wherein the carboxylic acid group is amidated with metylamine. The Glc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer structure had strong binding towards *H. pylori* and Glc(A-

methylamide) $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer had very strong binding to

- 20 *Helicobacter pylori*.

Production of GlcA $\beta$ 3Gal $\beta$ 4Glc(NAc) by transglycosylation

The acceptor saccharide Gal $\beta$ 4Glc or Gal $\beta$ 4GlcNAc (about 10-20 mM) is incubated with 10 fold molar excess paranitrophenyl-beta-glucuronic acid and bovine liver  $\beta$ -glucuronidase (20 000U, Sigma) in buffer having pH of about 5 for two days at 37

25 degrees of Celsius stirring the solution. The product is purified by HPLC.

## References

- Aggarwal, B. B., Eessalu, T. E. and Hass, P. E. (1985) *Nature*, **318**, 665-667.
- Andersson, B., Porras, O., Halson, L.Å., Lagergård, T., and Svanborg-Edén, C. (1986)  
 5 *J. Inf. Dis.* 153, 232-7
- Ångström, J., Teneberg, S., Abul Milh, M., Larsson, T., Leonardsson, I., Olsson, B.-M.,  
 Ölwegård Halvarsson, M., Danielsson, D., Näslund, I., Ljung, Å., Wadström, T. and  
 Karlsson, K.-A. (1998) *Glycobiology*, **8**, 297-309.
- Ascencio, F., Fransson, L-Å. and Wadström, T. (1993) *J. Med. Microbiol.*, **38**, 240-244.
- 10 Appelmelk, B.J., Faller, G., Claves, D., Kirchner, T., and Vandenbroucke-Grauls,  
 C.M.J.E. (1998) *Immol. Today* **19**, 296-299.
- Avenauid, P., Marais, A., Monteiro, L., Le Bail, B., Biolac Saga, P., Balabaud, C., and  
 Mégraud, F. (2000) *Cancer* **89**, 1431-1439.
- Axon, A. T. R. (1993) *J. of Antimicrobial Chemotherapy*, **32**, 61-68.
- 15 Babior, B. M. (1978) *N. Eng. J. Med.*, **298**, 659-668.
- Blaser, M. J. (1992) *Eur. J. Gastroenterol. Hepatol.*, **4** (suppl 1), 17-19.
- Bock, K., Breimer, M. E., Brignole, A., Hansson, G. C., Karlsson, K.-A., Larson, G.,  
 Leffler, H., Samuelsson, B. E., Strömberg, N., Svanborg-Edén, C. and Thurin, J.  
 (1985) *J. Biol. Chem.*, **260**, 8545-8551.
- 20 Borén, T., Falk, P., Roth, K. A., Larson, G. and Normark, S. (1993) *Science*, **262**, 1892-  
 1895.
- Breg, J., Kroon-Batenburg, L. M. J., Strecker, G., Montreuil, J. and Vliegthart, F. G.  
 (1989) *Eur. J. Biochem.*, **178**, 727-739.
- Castagliuolo, I., La Mont, J. T., Qiu, B., Nikulasson, S. T., and Pothoulakis, C. (1996)  
 25 *Gastroenterology* **111**, 433-438.
- Castronovo, V., Colin, C., Parent, B., Foidart, J.-M., Lambotte, R., and Mahieu, P. (1989) *J.*  
*Natl. Cancer Inst.*, **81**, 212-216
- Charlwood, J., Tolson, D., Dwek, M., and Camillen, P. (1999) *Anal. Biochem.*, **273**, 261-77.
- Clausen, H., Lavery, S.B., Kannagi, R. and Hakomori, S.-i. (1986) *J. Biol.*  
 30 *Chem.*, **261**, 1380-1387.
- Chmiela, M., Wadström, T., Folkesson, H., Planeta Malecka, I., Czekwianianc, E.,  
 Rechcinski, T., and Rudnicka, W. (1998) *Immunol. Lett.* **61**, 119-125.
- Claeys, D., Faller, G., Appelmelk, B.J., Negrini, R., and Kirchner, T. (1998)  
*Gastroenterology* **115**, 340-347.
- 35 Correa, T.L., Fox, J., Fontham, E., Ruiz, b., Lin, Y., zaula, D., Taylor, N., Mackinley, D.,  
 deLima, E., Portilla, H., Zarama, G. (1990) *Cancer* **66**, 596-574.
- DeCross, A. J. and Marshall, B. J. (1993) *Am. J. Med. Sci.*, **306**, 381-392.

- Dooley, C.P. (1993) *Curr. Opin. Gastroenterol.*, **9**, 112-117.
- Dubois, M., Gilles, K.A., Hamilton, J.K., Rebers, P.A. and Smith, F. (1956) *Analytical Chemistry* **28**, 350-356.
- Dunn, B.E., Cohen, H. and Blaser, M.J. (1997) *Clin. Microbiol. Rev.*, **10**, 720-741.
- 5 Ernst, B., Hart, G.W., and Sinaÿ, P. (eds.) (2000) *Carbohydrates in Chemistry and Biology*, ISBN 3-527-29511-9, Wiley-VCH, Weinheim.
- Eto, T., Ichikawa, Y., Nishimura, K., Ando, S. and Yamakawa, T. (1968) *J. Biochem. (Tokyo)*, **64**, 205-213.
- Evans, D. G., Evans Jr, D.J., Molds, J. J., and Graham, D. Y. (1988) *Infect. Immun.*, **56**,  
10 2896-06
- Falk, K.-E., Karlsson, K.-A. and Samuelsson, B. E. (1979a) *Arch. Biochem. Biophys.*, **192**, 164-176.
- Falk, K.-E., Karlsson, K.-A. and Samuelsson, B. E. (1979b) *Arch. Biochem. Biophys.*, **192**, 177-190.
- 15 Falk, K.-E., Karlsson, K.-A. and Samuelsson, B. E. (1979c) *Arch. Biochem. Biophys.*, **192**, 191-202.
- Farsak, B., Yildirim, A., Akyön, Y., Pinar, A., Öç, M., Böke, E., Kes, S., and Tokgözoğlu, L. (2000) *J. clin. Microbiol.* **38**, 4408-4411.
- Folch, J., Lees, M., And Sloane-Stanley, G.H. (1957) *J. Biol. Chem.* **226**, 497-509.
- 20 Fukuda, M. N., Dell, A., Oates, J. E., Wu, P., Klock, J. C. and Fukuda, M. (1985) *J. Biol. Chem.*, **260**, 1067-1082.
- Handa, S. (1963) *Jap. J. Exp. Med.*, **33**, 347-360.
- Hansson, G. C., Karlsson, K.-A., Larson, G., Strömberg, N. and Thurin, J. (1985) *Anal. Biochem.*, **146**, 158-163.
- 25 Hansson, G.C. and Karlsson, H. (1990) *Methods Enzymol.*, **193**, 733-738.
- Hu, J., Stults, C.L., Holmes, E.H., and Macher, B.A. (1994) *Glycobiology* **4**, 251-7.
- Ilver, D., Arnqvist, A., Ogren, J., Frick, I. M., Kersulyte, D., Incecik, E. T., Berg, D. E., Covacci, A., Engstrand, L., and Boren T. (1998) *Science*, **279**(5349), 373-377.
- 30 Ito, M. and Yamagata, T. (1989) *Methods Enzymol.*, **179**, 488-496.
- Jassel, S.V., Ardill, J.E.S., Fillmore, D., Bamford, K.B., O'Connor, F.A., and Buchanan, K.D. *Q. J. Med.* **92**, 373-377.
- Kannagi, R., Levine, P., Watanabe, K. and Hakomori, S.-i. (1982b) *Cancer Res.*, **42**, 5249-5254.
- 35 Karlsson, N. G., Olson, F. J., Jovall, P.-Å, Andersch, Y., Enerbäck, L., and Hansson G. C. (2000) *Biochem. J.*, **350**, 805-814.
- Karlsson, K.-A. (1987) *Meth. Enzymol.*, **138**, 212-220.

- Karlsson, K.-A. (1989) *Annu. Rev. Biochem.*, **58**, 309-350.
- Karlsson, K.-A. and Larsson, G. (1981a) *J. Biol. Chem.* **256**, 3512-3524.
- Karlsson, K.-A. and Larsson, G. (1981b) *FEBS Lett.*, **128**, 71-74.
- Kerr, J.R., Al-Khattaf, A., Barson, A.J., and Burnie, J.P. (2000) *Arch. Child. Dis.*, **83**, 429-434
- 5
- Koerner Jr, T. A. W., Prestegard, J. H., Demou, P. C. and Yu, R. K. (1983) *Biochemistry*, **22**, 2676-2687.
- Koscielak, J., Piasek, A., Gorniak, H., Gardas, A. and Gregor, A. (1973) *Eur. J. Biochem.*, **37**, 214-215.
- 10
- Laine, R. A., Stellner, K. and Hakomori, S.-i. (1974) *Meth. Membr. Biol.*, **2**, 205-244.
- Lanne, B., Uggla, L., Stenhagen, G., And Karlsson, K.-A. (1995) *Biochemistry* **34**, 1845-1850
- Lanne, B., Miller-Podraza, H., Abul Milh, M., Teneberg, S., Uggla, L., Larsson, T., Leonardsson, I., Jovall, P.-Å., Bergström, J. and Karlsson, K.-A. (2001)
- 15
- manuscript in preparation
- Larsen, R. D., Rivera-Marrero, C. A., Ernst, L. K., Cummings, R. D. and Lowe, J. B. (1990) *J. Biol. Chem.*, **265**, 7055-7061.
- Larson, G., Karlsson, H., Hansson, G.C. and Pimlott, W. (1987) *Carbohydr. Res.*, **161**, 281-290
- 20
- Ledeer, R. and Yu, R. K. (1978) *Res. Methods Neurochem.*, **4**, 371-410.
- Lin, J.-T., Wang, J.-T., Wang, M.-S., Wu, M.-S. and Chen, C.-J. (1993) *Hepato-Gastroenterol.*, **40**, 596-599.
- Lingwood, C. A., Huesca, M. and Kuksis, A. (1992) *Infect. Immun.*, **60**, 2470-2474.
- Mayo, S. L., Olafsen, B. D. and Goddard III, W. A. (1990) *J. Chem. Phys.*, **94**, 8897-8909.
- 25
- McKibbin, J. M., Spencer, W. A., Smith, E. L., Månsson, J. E., Karlsson, K.-A., Samuelsson, B. E., Li, Y.-T and Li, S. C. (1982) *J. Biol. Chem.*, **257**, 755-760.
- Meyer, B. (1990) *Topics Curr. Chem.*, **154**, 141-208.
- Miller-Podraza, H., Abul Milh, M., Bergström, J. and Karlsson, K.-A. (1996) *Glycoconj. J.*, **13**, 453-460.
- 30
- Miller-Podraza, H., Bergström, J., Abul Milh, M. and Karlsson, K.-A. (1997a) *Glycoconj. J.*, **14**, 467-471.
- Miller-Podraza, H., Abul Milh, M., Teneberg, S. and Karlsson, K.-A. (1997b) *Infect. Immun.*, **65**, 2480-2482.
- Miller-Podraza, H., Abul Milh, M., Ångström, J., Jovall, P.-Å., Wilhelmsson, U., Lanne, B., Karlsson, H., and Karlsson, K.-A. (2001) manuscript in preparation.
- 35
- Muzzarelli, R.A.A., Mattioli-Belmonte, M., Miliani, M., Muzzarelli, C., Gabbanelli, F., and Biagini, G. (2002) *Carbohydrate Polym.* **48**, 15-21

- Muzzarelli, R.A.A., Muzzarelli, C., Cosani, A., and Terbojevich, M. (1999) Carbohydrate Polym. **39**, 361-367
- Mysore, J.V., Wiggington, T., Simon, P.M., Zopf, D., Heman-Ackah, L.M. and Dubois, A. (1999) *Gastroenterology*, **117**, 1316-1325
- 5 Naiki, M., Fong, J., Ledeen, R. and Marcus, D. M. (1975) *Biochemistry*, **14**, 4831-4836.
- Nakhla, T., Fu, D., Zopf, D., Brodsky, N., and Hurt, H. (1999) *British J. Nutr.* **82**, 361-367.
- Needs, P.W. and Selvendran, R.R. (1993) *Carbohydr. Res.*, **245**, 1-10.
- Nilsson, H.-O., Taneera, J., Castedal, M., Glatz, E., Olsson, R., and Wadström, T. (2000) *J. Clin. Microbiol.* **38**, 1072-1076.
- 10 Nilsson, O., Månsson, J.-E., Tibblin, E. and Svennerholm, L. (1981) *FEBS Lett.*, **133**, 197-200.
- Nomenclature of glycoproteins (1988) *J. Biol. Chem.*, **262**, 13-18.
- Nomura, A. and Stemmermann, G. N. (1993) *J. Gastroenterol. Hepatol.*, **8**, 294-303.
- Nyholm, P. G., Samuelsson, B. E., Breimer, M. and Pascher, I. (1989) *J. Mol. Recog.*, **2**, 103-113.
- 15 Nyholm, P.-G. and Pascher, I. (1993) *Biochemistry*, **32**, 1225-1234.
- Ofek, I. and Sharon, N. (1988) *Infect. Immun.*, **56**, 539-547.
- Pakodi, F., Abdel-Salam, O.M.E., Debraceni, A., and Mozsik, G. (2000) *J. Physiol. (Paris)*, **94**, 139-152.
- 20 Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Chang, Y., Vogelmann, J.H., Orentreich, N. and Sibley, R.K. (1991) *N. Engl. J. Med.*, **325**, 1127-31
- Rappé, A. K. and Goddard III, W. A. (1991) *J. Chem. Phys.*, **95**, 3358-3363.
- Rautelin, H., Blomberg, B., Järnerot, G. and Danielsson, D. (1994a) *Scand. J. Gastroenterol.*, **29**, 128-132.
- 25 Rautelin, H., von Bonsdorff, C.-H., Blomberg, B. and Danielsson, D. (1994b) *J. Clin. Pathol.*, **47**, 667-669.
- Rebora, R., Drago, F., and Parodi, A. (1995) *Dermatology* **191**, 6-8.
- Saitoh, T., Natomi, H., Zhao, W., Okuzumi, K., Sugano, K., Iwamori, M. and Nagai, Y. (1991) *FEBS Lett.*, **282**, 385-387.
- 30 Samuelsson, B. E., Pimlott, W. and Karlsson, K.-A. (1990) *Meth. Enzymol.*, **193**, 623-646.
- Sears, P., and Wong, C-H. (1996) *Proc. Natl. Acad. Sci.*, **93**, 12086-12093.
- Siebert, H.-C., Reuter, G., Schauer, R., von der Lieth, C.-W. and Dabrowski, J. (1992) *Biochemistry*, **31**, 6962-6971.
- Simon, P. M., Goode, P. L., Mobasser, A., and Zopf, D. (1997) *Infect. Immun.* **65**, 750-757
- 35 Soltesz, V., Schalen, C. and Mårdh, P. A. (1988) *Proceedings of the Fourth International Workshop on Campylobacter Infections* (Kaijser, B. and Falsen, E., eds.) pp. 433-436, Goterna, Kungälv, Sweden.



- Steininger, H., Faller, G., Dewald, E., Brabletz, T., Jung, A., and Kirchner, T. (1998) *Virchows Arch.* **433**, 13-18.
- Stellner, K., Saito, H. and Hakomori, S.-i. (1973) *Arch. Biochem. Biophys.*, **155**, 464-472.
- Stellner, K. and Hakomori, S.-i. (1974) *J. Biol. Chem.*, **249**, 1022-1025.
- 5 Stroud, M. R., Handa, K., Salyan, M. E. K., Ito, K., Lavery, S. B., Hakomori, S.-i., Reinhold, B. B. and Reinhold, V. N. (1996) *Biochemistry*, **35**, 758-769.
- Sung, J., Russell, R.I., Neyomans, Chan, F.K., Chen, S., Fock, K., Goh, K.L., Kullavanijaya, P., Kimura, K., Lau, C., Louw, J., Sollano, J., Triadialafalopulos, G., Xiao, S., Brooks, P. (2000) *J. Gastroenterol. Hepatol.*, **15**, Suppl: G58-68.
- 10 Teneberg, S., Ångström, J., Jovall, P.-Å. and Karlsson, K.-A. (1994) *J. Biol. Chem.*, **269**, 8554-8563.
- Teneberg, S., Lönnroth, I., Torres Lopez, J. F., Galili, U., Ölwegård Halvarsson, M., Ångström, J. and Karlsson, K.-A. (1996) *Glycobiology*, **6**, 599-609.
- Teneberg, S., Abul Milh, M., Lanne, B., Jovall, P.-Å., Karlsson, H., Ångström, J., Ölwegård
- 15 Halvarsson, M., Danielsson, D., Ljung, Å., Wadström, T. and Karlsson, K.-A. (2001, manuscript in preparation).
- Thorn, J. J., Lavery, S. B., Salyan, M. E. K., Stroud, M. R., Cedergren, B., Nilsson, B., Hakomori, S.-i. and Clausen, H. (1992) *Biochemistry*, **31**, 6509-6517.
- Thurin, J., Brodin, T., Bechtel, B., Jovall, P.-Å., Karlsson, H., Strömberg, N., Teneberg, S.,
- 20 Sjögren, H. O. and Karlsson, K.-A. (1989) *Biochim. Biophys. Acta*, **1002**, 267-272.
- Vivier, E., Sorrell, J. M., Ackerly M., Robertson M. J., Rasmussen R. A., Levine H., and Anderson P. (1993) *J. Exp. Med.*, **178**(6), 2023-33.
- Waldi, D. (1962) in *Dünnschicht-Chromatographie* (Stahl, E., ed.) pp. 496-515, Springer-Verlag, Berlin.
- 25 Watanabe, K. and Hakomori, S.-i. (1979) *Biochemistry*, **18**, 5502-5504.
- Wells, M.E. and Dittmer, J.C. (1963) *Biochemistry*, **2**, 1259-1263.
- Wotherspoon, A.C., Doglioni, C., Diss, T.C., Pan, L., Moschini, A., de Boni, M. and Isaacson, P.G. (1993) *Lancet*, **342**, 575-577
- Yamakawa, T. (1966) *Colloq. Ges. Physiol. Chem.*, **16**, 87-111.
- 30 Yang, H.-j. and Hakomori, S.-i. (1971) *J. Biol. Chem.*, **246**, 1192-1200.

What is claimed:

1. Use of a substance comprising *Helicobacter pylori* binding oligosaccharide sequence

5

$[\text{Gal}(\text{A})_q(\text{NAc})_r/\text{Glc}(\text{A})_q(\text{NAc})_r \alpha 3/\beta 3]_s [\text{Gal}\beta 4\text{GlcNAc}\beta 3]_t \text{Gal}\beta 4\text{Glc}(\text{NAc})_u$

wherein q, r, s, t, and u are each independently 0 or 1,

10 so that when t = 0 and u = 0, then the oligosaccharide sequence is linked to a polyvalent carrier or present as a free oligosaccharide in high concentration, and analogs or derivatives of said oligosaccharide sequence having binding activity to *Helicobacter pylori* for the production of a composition having *Helicobacter pylori* binding or inhibiting activity.

15

2. The use according to claim 1, wherein said substance comprises the oligosaccharide sequence

$\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{GlcNAc}$  or  $\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}$

20

where position C4 of terminal  $\text{GlcNAc}\beta 3$  is optionally linked to  $\text{Gal}\beta 1$ - or an oligosaccharide chain by a glycosidic bond.

3. The use according to claim 1, wherein said substance comprises one or several of  
25 the following oligosaccharide sequences

$\text{Gal}\beta 4\text{GlcNAc}$ ,

$\text{GalNAc}\alpha 3\text{Gal}\beta 4\text{GlcNAc}$ ,  $\text{GalNAc}\beta 3\text{Gal}\beta 4\text{GlcNAc}$ ,  $\text{GlcNAc}\alpha 3\text{Gal}\beta 4\text{GlcNAc}$ ,

30  $\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{GlcNAc}$ ,  $\text{Gal}\beta 3\text{Gal}\beta 4\text{GlcNAc}$ ,  $\text{Glc}\alpha 3\text{Gal}\beta 4\text{GlcNAc}$ ,  $\text{Glc}\beta 3\text{Gal}\beta 4\text{GlcNAc}$ ,

$\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{GlcNAc}$ ,  $\text{Gal}\beta 4\text{GlcNAc}\beta 3\text{Gal}\beta 4\text{Glc}$ ,

- GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,  
 GlcNAc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,  
 Gal $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, Glc $\alpha$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,  
 5 Glc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc,
- GalANAc $\beta$ 3Gal $\beta$ 4GlcNAc, GalANAc $\alpha$ 3Gal $\beta$ 4GlcNAc, GalA $\beta$ 3Gal $\beta$ 4GlcNAc,  
 GalA $\alpha$ 3Gal $\beta$ 4GlcNAc, GalANAc $\beta$ 3Gal $\beta$ 4Glc, GalANAc $\alpha$ 3Gal $\beta$ 4Glc, GalA $\beta$ 3Gal $\beta$ 4Glc,  
 GalA $\alpha$ 3Gal $\beta$ 4Glc,  
 10 GlcANAc $\beta$ 3Gal $\beta$ 4GlcNAc, GlcANAc $\alpha$ 3Gal $\beta$ 4GlcNAc, GlcA $\beta$ 3Gal $\beta$ 4GlcNAc,  
 GlcA $\alpha$ 3Gal $\beta$ 4GlcNAc, GlcANAc $\beta$ 3Gal $\beta$ 4Glc, GlcANAc $\alpha$ 3Gal $\beta$ 4Glc, GlcA $\beta$ 3Gal $\beta$ 4Glc,  
 GlcA $\alpha$ 3Gal $\beta$ 4Glc,
- 15 Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc, and reducing-end polyvalent  
 conjugates thereof.
4. The use according to claim 1, wherein said substance comprises one or several of  
 the following oligosaccharide sequences  
 20 GalNAc $\alpha$ 3Gal $\beta$ 4Glc, GalNAc $\beta$ 3Gal $\beta$ 4Glc, GlcNAc $\alpha$ 3Gal $\beta$ 4Glc,  
 GlcNAc $\beta$ 3Gal $\beta$ 4Glc, Gal $\beta$ 3Gal $\beta$ 4Glc, Glc $\alpha$ 3Gal $\beta$ 4Glc, Glc $\beta$ 3Gal $\beta$ 4Glc, and  
 reducing-end polyvalent conjugates thereof.
- 25 5. The use according to claim 3, wherein said substance comprises one or several of  
 the following oligosaccharide sequences
- Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc (lacto-N-neotetraose),  
 Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4Glc (para-lacto-N-neohexaose), and  
 30 reducing-end polyvalent conjugates thereof.

6. The use according to any one of claims 1 – 5, wherein said substance is conjugated to a polysaccharide, preferably to a polylactosamine chain or a conjugate thereof.
- 5 7. The use according to any one of claims 1 – 5, wherein said substance is a glycolipid.
8. The use according to any one of claims 1 – 5, wherein said substance is an oligomeric molecule containing at least two or three oligosaccharide chains.
- 10 9. The use according to any one of claims 1 – 5, wherein said substance consists of a micelle comprising one or more of the substances as defined in claims 1 – 8.
10. The use according to any one of claims 1 – 9, wherein said substance(s) is/are conjugated to a carrier.
- 15 11. The use according to any one of claims 1 - 10, wherein said substance is covalently conjugated with an antibiotic effective against *Helicobacter pylori*, preferably a penicillin type antibiotic.
- 20 12. The use according to claim 10, wherein position C1 of reducing end terminal Glc or GlcNAc of said oligosaccharide sequence (OS) is oxygen linked (–O–) to an oligovalent or a polyvalent carrier (Z), via a spacer group (Y) and optionally via a monosaccharide or oligosaccharide residue (X), forming the following structure
- 25
- $$[\text{OS} - \text{O} - (\text{X})_n - \text{Y}]_m - \text{Z}$$
- where integers m, and n have values  $m \geq 1$ , and n is independently 0 or 1; X is preferably lactosyl-, galactosyl-, poly-N-acetyl-lactosaminyl, or part of an O-glycan or an N-glycan oligosaccharide sequence, Y is a spacer group or a terminal conjugate such as a ceramide lipid moiety or a linkage to Z;
- 30

or a derivative of the substance of said structure having binding activity to *Helicobacter pylori*.

13. Use of the substance as defined in claims 1 - 12 for the production of a  
5 pharmaceutical composition for the treatment or prophylaxis of any condition due to the presence of *Helicobacter pylori*.

14. The use according claim 13, wherein said pharmaceutical composition is for the treatment of chronic superficial gastritis, gastric ulcer, duodenal ulcer, gastric  
10 adenocarcinoma, non-Hodgkin lymphoma in human stomach, liver disease, pancreatic disease, skin disease, heart disease, or autoimmune diseases including autoimmune gastritis and pernicious anaemia and non-steroid anti-inflammatory drug (NSAID) related gastric disease, or for prevention of sudden infant death syndrome.

15  
15. Use of the substance as defined in claims 1 - 12, for the diagnosis of a condition due to infection by *Helicobacter pylori*.

16. Use of the substance as defined in claims 1 - 12 for the production of a  
20 nutritional additive or composition for the treatment or prophylaxis of any condition due to the presence of *Helicobacter pylori*.

17. The use according to claim 16 wherein said nutritional additive or composition is for infant food.


25  
18. Use of the substance as defined in claims 1 – 12, for the identification of bacterial adhesin.

19. Use of the substance as defined in claims 1 – 12 or a substance identified  
30 according to claim 18, for the production of a vaccine against *Helicobacter pylori*.

20. Use of the substance as defined in claims 1 – 12 for typing *Helicobacter pylori*.

21. Use of the substance as defined in claims 1 – 12 for *Helicobacter pylori* binding assays.

22. A *Helicobacter pylori* binding substance comprising an oligosaccharide  
5 sequence




wherein q, r and u are independently 0 or 1,  
10

with the proviso that when said oligosaccharide sequence contains  $\beta 3$  linkage, both q and r are 0 or 1; or

$\text{GalA(NAc)}_r \alpha 3/\beta 3 \text{Gal} \beta 4 \text{Glc(NAc)}_u$   
15


wherein r and u are independently 0 or 1, and *Helicobacter pylori* binding analogs and derivatives thereof.

23. A *Helicobacter pylori* binding non-acidic polyvalent substance comprising the  
20 oligosaccharide sequence as defined in claim 1, wherein said oligosaccharide sequence (OS) is a part of structure



25 as defined in claim 12, Y being a hydrophilic spacer, more preferably a flexible hydrophilic spacer, and *Helicobacter pylori* binding analogs and derivatives thereof.

24. The *Helicobacter pylori* binding non-acidic polyvalent substance according to claim 23, wherein linker structure Y is  
30



wherein  $L_1$  and  $L_2$  are linking groups comprising independently oxygen, nitrogen, sulphur or carbon linkage atom or two linking atoms of the group forming linkages such as  $-O-$ ,  $-S-$ ,  $-CH_2-$ ,  $-N-$ ,  $-N(COCH_3)-$ , amide groups  $-CO-NH-$  or  $-NH-CO-$  or  $-N-N-$  (hydrazine derivative) or an amino oxy-linkages  $-O-N-$  and  $-N-O-$ ;  $L_1$  is linkage from carbon 1 of the reducing end monosaccharide of X or when  $n=0$ ,  $L_1$  replaces  $-O-$  and links directly from the reducing end C1 of OS;  $p_1, p_2, p_3$ , and  $p_4$  are independently integers from 0-7, with the proviso that at least one of  $p_1, p_2, p_3$ , and  $p_4$  is at least 1;  $CH_{1-2}OH$  in the branching term  $\{CH_{1-2}OH\}_{p_1}$  means that the chain terminating group is  $CH_2OH$  and when the  $p_1$  is more than 1 there is secondary alcohol groups  $-CHOH-$  linking the terminating group to the rest of the spacer; R is preferably acetyl group ( $-COCH_3$ ) or R is an alternative linkage to Z and then  $L_2$  is one or two atom chain terminating group, in another embodiment R is an analog forming group comprising  $C_{1-4}$  acyl group comprising amido structure or H or  $C_{1-4}$  alkyl forming an amine; and  $m > 1$  and Z is polyvalent carrier; OS and X are as defined in claim 12.

25. A *Helicobacter pylori* binding substance comprising the oligosaccharide sequence

20  $Gal(A)_q(NAc)_r / Glc(A)_q(NAc)_r \alpha 3 / \beta 3 Gal \beta 4 Glc(NAc)_u$

wherein  $q, r$  and  $u$  are each independently 0 or 1, with the proviso that said oligosaccharide sequence is not  $Gal \alpha 3 Gal \beta 4 Glc / GlcNAc$ ,

25 as a non-reducing end terminal sequence, and *Helicobacter pylori* binding analogs and derivatives thereof.

26. The substance according to any one of claims 22-25 for use in binding bacteria, toxins or viruses.

30

27. The substance according to any one of claims 22-25 for use as a medicament.

28. A method for the treatment of a condition due to presence of *Helicobacter pylori*, wherein a pharmaceutically effective amount of the substance as defined in any one of claims 1 – 12 or 22-25 is administered to a subject in need of such treatment.

5 29. The method according to claim 28, when said condition is caused by the presence of *Helicobacter pylori* in the gastrointestinal tract of a patient.

30. The method according to claim 28, for the treatment of chronic superficial gastritis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma, non-Hodgkin  
10 lymphoma in human stomach, liver disease, pancreatic disease, skin disease, heart disease, or autoimmune diseases including autoimmune gastritis and pernicious anaemia and non-steroid anti-inflammatory drug (NSAID) related gastric disease, or for prevention of sudden infant death syndrome.


15 31. The method of treatment according to any one of claims 28 – 30, wherein said substance is a nutritional additive or a part of a nutritional composition.

32. The substance according to claim 26, wherein said toxin is toxin a of *Clostridium difficile*.

20

33. The use according to claim 1, wherein said oligosaccharide sequence is  $\beta$ 1-6 linked from the reducing end to GalNAc, GlcNAc, Gal or Glc.

25 34. The use according to claim 2, wherein said oligosaccharide sequence is



q and r being as defined in claim 1.

30



1/14




Fig. 1A

2/14





Fig. 1B

3/14




Fig. 2A




Fig. 2B

4/14

Fig. 3A




Fig. 3B




Fig. 4A




Fig. 4B





Fig. 4C



1 2 3 4 5 1 2 6 7 2 3 6

Fig. 5B





Fig. 5A



7/14

Fig. 6A





Fig. 6B

Fig. 7B





Fig. 7A





9/14




Fig. 8A

Fig. 8B

10/14




Fig. 8C

Fig. 8D

11/14




Fig. 9A

Fig. 9B

12/14




Fig. 9C

Fig. 9D

Fig. 10




Fig. 11C




Fig. 11B





Fig. 11A



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00043

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/702, C07H 15/04, C07H 3/06, A61P 1/04, A61P 31/04  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C07H, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, CHEM.ABS.DATA, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 0143751 A1 (A+ SCIENCE INVEST AB), 21 June 2001 (21.06.01)  --	1,6-21, 23-24,26-33
X	Glycobiology, Volume 8, No. 4, 1998, Jonas Ångström et al: "The lactosylceramide binding specificity of Helicobacter pylori", pages 297-309  --	1-33
X	Infection and Immunity, June 1993, B.D. Gold et al: "Helicobacter mustelae and Helicobacter pylori Bind to Common Lipid Receptors in Vitro", pages 2632-2638  --	1-33

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

22 April 2002

Date of mailing of the international search report

25 -04- 2002

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

EVA JOHANSSON/BS

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00043

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Archives of Biochemistry and Biophysics, Volume 277, No. 1, February, 1990, Eric H. Holmes et al: "Characterization of Two Monoclonal Antibodies Specific for Lacto-Series Type 1 Chain Gal $\beta$ 1-3GlcNAc- Terminal Structures", pages 181-188  --	1-33
X	EP 0098252 B1 (BIOCARB AB), 11 January 1984 (11.01.84)  --	1-33
X	WO 8604065 A1 (SYNTEK AB), 17 July 1986 (17.07.86)  --	1-33
A	Glycoconjugate Journal, Volume 18, 2001, Maan Abul-Milh et al: "In vitro binding of Helicobacter Pylori to Monohexosylceramides", pages 253-260  --	1-33
A	J. Biochem., Volume 108, 1990, Per Falk et al: "Bacteria of the Human Intestinal Microbiota Produce Glycosidases Specific for Lacto-Series Glycosphingolipids", pages 466-474  --	1-33
A	Infection and Immunity, Volume 65, No. 6, June, 1997, Halina Miller-Podraza et al: "Binding of Helicobacter pylori to Sialic Acid-Containing Glycolipids of Various Origins Separated on Thin-Layer Chromatograms", pages 2480-2482  --	1-33
A	Patent Abstracts of Japan, abstract of JP,A,10045602 (MURAKAMI MOTOYASU; KAKEN PHARMACEUT CO LTD), 17 February 1998 (17.02.98)  --	1-33
A	EP 0089938 A1 (SVENSKA SOCKERFABRIKS AB), 28 Sept 1983 (28.09.83)  -- -----	1-33



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/FI02/00043

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15, 18, 28-31  
because they relate to subject matter not required to be searched by this Authority, namely:  
see next sheet
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/FI02/00043

Claims 15,18,28-31 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

28/01/02

International application No.

PCT/FI 02/00043

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0143751	A1	21/06/01	AU	2418801 A	25/06/01
				SE	9904581 D	00/00/00
-----						
EP	0098252	B1	11/01/84	SE	0098252 T3	
				AT	43847 T	15/06/89
				DE	3380025 D	00/00/00
				DK	284283 A	24/12/83
				FI	78707 B,C	31/05/89
				FI	832254 A	24/12/83
				JP	59025399 A	09/02/84
				SE	8203925 D	00/00/00
				US	4675392 A	23/06/87
-----						
WO	8604065	A1	17/07/86	AT	42559 T	15/05/89
				AU	588854 B	28/09/89
				AU	5351586 A	29/07/86
				CA	1316170 A	13/04/93
				CN	1022687 B	10/11/93
				CN	86100178 A	15/07/87
				DE	3663029 D	00/00/00
				DK	17685 D	00/00/00
				DK	439486 A	12/09/86
				EP	0208749 A,B	21/01/87
				SE	0208749 T3	
				FI	83659 B,C	30/04/91
				FI	863703 A	12/09/86
				IE	58778 B	17/11/93
				IL	77602 A	13/05/93
				JP	2510176 B	26/06/96
				JP	62502258 T	03/09/87
				NO	166865 B,C	03/06/91
				NO	863645 A	13/11/86
				US	4868289 A	19/09/89
-----						
EP	0089938	A1	28/09/83	SE	0089938 T3	
				AT	29385 T	15/09/87
				AU	561067 B	30/04/87
				AU	1263183 A	29/09/83
				DE	3373415 D	00/00/00
				DK	130883 A	23/09/83
				FI	830958 A	23/09/83
				JP	58172319 A	11/10/83
				NO	831010 A	23/09/83
				US	4665060 A	12/05/87
				US	4851338 A	25/07/89
-----						